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ABSTRACT 
Disruption of normal mammary epithelial cell homeostasis through acquisition of 
deleterious somatic and/or germline mutations leads to breast cancer development. Breast 
cancer is the most commonly diagnosed cancer among women worldwide, and is 
associated with the second highest amount of cancer-related deaths. Breast cancer 
mortality rates are decreasing, likely through increased methods of detection and 
development of targeted therapies. However, due to the complexity and heterogeneity of 
the disease, the incidence rate remains high and the molecular events that lead to breast 
cancer initiation and progression are poorly understood. 
The epithelial-to-mesenchymal transition (EMT) is an essential molecular process 
involved in the initiation and progression of epithelial-based tumors. Loss of cell-cell 
connections, altered extracellular matrix interactions, and dramatic cytoskeletal changes 
promote cell individuality and development of a migratory and often invasive phenotype. 
Under normal physiological conditions, EMT is involved in processes such as embryonic 
development and wound healing. EMT is tightly regulated by a combination of signaling 
pathways and epigenetic factors. However, the molecular mechanisms that suppress EMT 
within the normal epithelium to prevent tumorigenesis remain understudied. 
Mitotic gene bookmarking – retention of cell lineage-specific transcription factors 
with target genes, together with histone modifications, specific DNA methylation 
patterns, and components of transcriptional machinery on mitotic chromosomes – is an 
epigenetic mechanism that maintains cellular identity throughout successive cell 
divisions. Mitotic occupancy and post-mitotic transcription regulation of target genes 
involved in proliferation, growth, and cellular identity by transcription factors, re- 
establishes epithelial-specific transcriptional programs in newly formed progeny cells. 
The RUNX1-CBFβ heterodimeric transcription factor complex is essential for 
normal mammary gland development. Mutations in both subunits have been identified in 
breast cancers. Studies by our group have shown that RUNX proteins act as mitotic 
bookmarks in a variety of tissue types and depletion of RUNX1 in normal mammary 
epithelial cells leads to EMT. Findings reported in this study show that inhibition of the 
RUNX1-CBFβ interaction disrupts the normal mammary epithelial phenotype, alters cell 
cycle regulation, and initiates EMT. Furthermore, results demonstrate RUNX1 is 
maintained on mitotic chromosomes during all topologically identifiable stages of mitosis 
in live MCF10A cells. Conditions and methods have been optimized to study the specific 
function of the RUNX1-CBFβ transcription factor complex as a mitotic bookmark, 
essential for mitotic and post-mitotic transcriptional regulation of genes involved in 
proliferation, cell growth, and epithelial cell identity throughout successive cell divisions. 
Further studies utilizing these conditions and methods are required to address the 
functional role of the RUNX1-CBFβ transcription factor complex as an essential mitotic 
bookmark involved in phenotypic maintenance in the normal mammary epithelium. 
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CHAPTER 1: BREAST CANCER 
1.1. Overview 
Breast cancer is a complex and heterogeneous disease that develops from an
accumulation of mutations, leading to the formation of multipotent cells with the ability
to proliferate and grow uncontrollably. Breast cancer has the highest incident rate of all 
cancers among women worldwide. Current statistics indicate that on average, each 
woman has a 1 in 8 chance of developing breast cancer in her lifetime [1, 2] and 
approximately 30% of these women will eventually develop metastatic disease [3]. 
According to the National Cancer Institute, breast cancer presents most commonly in 
individuals over the age of 55. However, many young adults are also affected, leading to 
psychological disturbances which often extend far beyond the diseased individual, 
disrupting social and family life [4]. Although breast cancer incidence rates have 
remained relatively steady in recent years, mortalities have decreased in the United States 
and world-wide, since the 1990s [2, 5]. This decrease has been attributed to increased 
awareness, routine screening, and improved early detection methods, as well as the 
reduced use of hormone replacement therapy and the development of targeted therapies 
[2, 6]. Despite these positive trends, breast cancer cases accounted for 30% of all cancer 
diagnoses in the United States among women in 2019 [1]. 
Breast cancer is considered one of the most treatable cancers with an average
five- year survival rate of approximately 90% [2]. However, due to its prevalence and 
continued disease progression still experienced by many patients, breast cancer accounts 
for the second highest group of cancer-related mortalities in women in the United States, 
topped only by lung cancer [1]. The complex heterogeneity of the disease leaves many 
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aspects of the malignancy poorly understood. Describing the molecular mechanisms that 
mediate disease initiation and progression will help to identify and diagnose clinical 
manifestations and will advance our ability to design and implement targeted therapies to 
improve patient outcome. 
1.2 Risk factors and clinical distinctions 
Many factors, both genetic and environmental, can place individuals at an 
increased risk for developing breast cancer along with other malignancies. Breast cancer 
is highly correlated with estrogen-related hormone signaling [7]. Accordingly, sex 
inherently plays the largest risk factor. In the United States, less than one percent of all 
breast cancer cases are diagnosed in men [8]. Family history has been clearly shown to 
influence risk [6, 9]. These patterns indicate inheritable genetic predispositions. Certain 
genetic mutations have been identified as major risk factors for breast cancer 
development. Most notably are germline mutations in the BRCA1 and BRCA2 genes. 
Together these two mutations are associated with a lifetime risk of approximately 70% 
[6, 10]. Both genes act as tumor suppressors and play important roles in DNA damage 
repair, thereby preventing cancer-associated genomic instability, irregular cell growth, 
and continued proliferation [11]. Clinically, BRCA1 mutations are associated with more 
aggressive, hormone receptor-negative tumors compared to BRCA2 mutations [10-12]. 
Additional driver gene mutations have been identified in breast cancer. The tumor 
suppressor TP53 is mutated in a wide variety of cancers, including breast carcinomas. 
Mutations in TP53 are associated with Li Fraumeni syndrome [13], which is known to 
increase lifetime risk of developing breast cancer, leukemia, and brain tumors, among 
others [6]. Other genes identified with germline mutations in breast cancer include PTEN, 
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CDH1, and CHEK2. Interestingly, only 5-10% of breast cancers are linked to inheritable 
genetic mutations [6]. These statistics suggest that although there is a clear correlation 
between germline, hereditary mutations and increased breast cancer risk, many other 
factors, including the accumulation of additional mutations, are required to promote 
tumorigenesis. 
Many non-genetic factors have been linked to increased risk of breast cancer. 
Differential trends in breast cancer have been identified by race and ethnicity. Overall, 
Caucasian women are most likely to develop any type of breast cancer, however, 
African-American women are more likely to develop breast cancer at a younger age [6]. 
These early age cancers tend to be more aggressive and are associated with increased 
mortality rates. Lifestyle choices may also impact breast cancer risk. For example, 
obesity and excessive alcohol consumption have been correlated to an increased risk of 
breast cancer development [6, 14]. Hormone-based contraception methods as well as 
hormone replacement therapy, often used during menopause both to relieve symptoms 
and prevent onset of osteoporosis, increase breast cancer risk due to elevated levels of 
hormone exposure [6, 13]. These findings clearly indicate that both genetic and non- 
genetic factors, influence a woman’s risk of developing breast cancer, and underscore the 
complexity and diversity of breast tumors. 
Breast cancer is a heterogeneous disease comprised of both clinically and 
molecularly distinct subtypes [9]. Recent advances in genomic and histologic 
technologies have allowed for the identification of such clinical and molecular 
differences and have paved the way for the development of targeted therapies. However, 
intratumoral heterogeneity increases pathologic complexity and decreases therapeutic 
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effectiveness. Classically, breast tumors are categorized based on certain morphological 
traits [15, 16]. Diagnostic and prognostic features include tumor grade and size, marginal 
status, and lymph node and vascular invasion [15, 17]. Biological markers that include 
estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), and human 
epidermal growth factor receptor 2 (HER2) are used to further classify tumor subtypes 
and determine treatment strategies [15, 18]. Large scale expression profiling has 
identified five basic intrinsic subtypes of breast cancer based on molecular make up: 
normal breast-like, luminal A, luminal B, HER2 overexpression, and basal-like (Fig. 1.1) 
[9]. These molecular differences can be determined by immunohistochemistry or 
fluorescence in situ hybridization to analyze gene amplification patterns. Importantly, 
gene overexpression is not always seen in conjunction with receptor amplification [19]. 
Molecular subtypes of breast cancer manifest disproportionally and are associated with 
variable clinical outcomes and prognoses. 
The luminal A subtype is the most common type of breast tumor, accounting for 
approximately 54% of all diagnosed cases. These tumors are characterized as ER+ and 
HER2- . The estrogen receptor (ESR-1) gene along with other estrogen signaling-related 
genes including GATA3, FOXA1, and LIV1 have been shown to be amplified [15]. 
Additionally, luminal cytokeratins such as CK8/18 show elevated expression in breast 
cancer [15, 18]. Based on these molecular features, Luminal A tumors bear the greatest
resemblance to the normal breast luminal epithelium. Some variety does exist within this 
group, with a subset of Luminal A tumors displaying HER2+ status [18]. Luminal A 
tumors are most commonly associated with a positive clinical outcome. Although these 
tumors do not readily respond to conventional chemotherapy regimens because of low 
Dai, X., et al. (2015). American journal of cancer research 5(10): 2929. 
Figure 1.1 Clinical subclasses and associated prognoses of breast cancers. The schematic, adapted 
from Dai et al (2015), depicts progression of breast cancer from hormone receptors (ER, HER2, PR) 
positive luminal subtype to the triple negative, basal-like subtype. Luminal A tumors are associated with 
the best clinical outcome and prognosis which progressively worsens with loss of hormone receptor 
expression. Basal-like, triple negative tumors are associated with the worst clinical outcome. Additionally, 
basal-like tumors are most frequently associated with BRCA1 germline mutations. 
5 
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proliferation rates, they are highly sensitive to hormone therapies due to ER expression, 
and patient relapse is infrequent [15, 20]. 
Like Luminal A, the Luminal B subtype displays CK8/18 cytokeratins. These 
tumors express lower levels of ER-related genes and display increased proliferation rates 
relative to their luminal A counterpart. A subset of this class is HER2+ [15, 18]. Due to 
these characteristics, the luminal B subtype is often of higher grade and is associated with 
an increased rate of recurrence and worse prognosis. For treatment purposes, it is 
essential to identify expression of HER2, or lack thereof, as therapeutic strategies vary 
greatly depending on the receptor expression status. 
The HER2+ subtype, also referred to as HER-2/neu-enriched, displays increased 
HER2 receptor expression, as indicated by the name. This subtype accounts for 
approximately 15% of all breast cancers [15]. These tumors are ER- and often exhibit 
TP53 mutations. HER2+ tumors are typically more aggressive than luminal tumors, a 
characteristic often attributed to lack of ER expression. Lymph node involvement is 
usually detected at the time of diagnosis and relapse is common. Due to increased 
proliferation, these tumors respond to general chemotherapy regiments which target 
actively proliferating cells. Targeted HER2 receptor inhibitors, such as the monoclonal 
antibody Trastuzumab, are frequently used treatment options [21]. The development of 
HER2 targeted therapies has significantly improved the prognosis for patients diagnosed 
with this subtype [15], however, resistance to such treatments often ensues [18]. 
Basal-like tumors are the most aggressive intrinsic subtype of breast cancers. The 
majority of these tumors are triple-negative, lacking expression of ER, AR, and HER2 
receptors, indicating their proliferation is not stimulated by classical hormone signaling. 
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Additionally, these tumors express basal-associated cytokeratins such as KRT5, KRT17, 
CX3CL1, and TRIM29, among others [15, 18], mimicking characteristics of mammary 
basal epithelial cells. Like HER2+ tumors, approximately 75% of basal tumors display 
TP53 mutations. These tumors are associated with an increased mitotic ratio, necrosis, 
and frequent lymph node metastases and spread to distal organs. Accordingly, the 
prognosis for basal-like tumors is poor. This subtype tends to present in a younger patient 
cohort [18]. Due to the lack of aberrant hormone receptor expression and signaling, the 
only pharmacological treatment option for these tumors is standard chemotherapy. 
Identifying mechanisms and molecular landscapes to develop targeted therapies for 
basal-like tumors is an active field of research. 
Recent studies have sought to further depict inter- and intra-tumor heterogeneity 
and as a result additional breast tumor subsets have been defined [15, 22]. These subtypes 
include Claudin-Low, which may be the most well defined, Molecular Aprocrine, and 
Interferon-Related [15]. Claudin-low tumors, like triple-negative, are associated with low 
to negative hormone signaling receptors. However, Claudin-low tumors display increased 
expression patterns of genes related to immune response, cellular differentiation, 
migration, and angiogenesis pathways [23]. The prognosis associated with these tumors 
reflects that of basal-like nature. The Molecular Aprocrine phenotype is defined by ER-, 
AR+, and increased ERRB2 (a member of the epidermal growth factor receptor family) 
expression [24] but are distinct from basal-like tumors. It has been hypothesized that 
ERRB2 expression may act to stabilize AR signaling [25]. The Interferon-Related 
subtype displays increased expression of interferon and proliferation-related genes such 
as STAT1 [26], which correspond with a worse prognosis. Future studies are required to  
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gain a deeper understanding of these subtypes and to develop effective targeted therapies.
Mammary epithelial cell homeostasis is maintained through a combination of 
genetic, epigenetic, and molecular regulatory mechanisms. The accumulation of 
mutations, the combination of which is often unique to each tumor, results in disruption 
of this homeostasis leading to increased stemness and clonal expansion of tumorigenic 
cells. Efforts to describe molecular signatures that may predict therapeutic response and 
prognosis have further highlighted both the inter- and intra-tumoral heterogeneity that 
exists within and between breast tumors [22, 27, 28]. Due to the complexity of breast 
cancer, many of the mechanisms that underlie tumor initiation, subtype differentiation, 
progression, and metastatic spread are not well understood. Deciphering the essential 
regulatory mechanisms required to maintain the normal mammary epithelial phenotype 
will provide insight into disease propagation and will help develop new methods for 
early detection and therapeutic intervention. 
9 
CHAPTER 2: EPITHELIAL-TO-MESENCHYMAL TRANSITION 
2.1. Overview 
Over the past three decades, major discoveries have been made in understanding 
the role of the epithelial-to-mesenchymal transition (EMT) under both normal and 
diseased cellular conditions [29]. The EMT is a trans-differentiation process during 
which epithelial cells lose epithelial phenotype-defining characteristics to gain a more 
migratory, and often invasive, mesenchymal phenotypes. This process was first described 
by Elizabeth Hay, who observed such morphological changes to the epithelial phenotype 
during formation of the primitive streak in chick embryos [30]. Subsequent studies have 
solidified the role of EMT in three major biological processes: embryonic differentiation 
and development, wound healing and fibrosis, and malignant transformation and 
progression of epithelial based tumors [29]. During EMT epithelial cells must undergo 
striking cytoskeletal alterations to promote cell motility and morphologic plasticity. Cell-
cell adhesions are lost, extracellular matrix (ECM) connections are altered, and cells 
develop front-rear polarity and individualize (Fig. 1.2). Indeed, dramatic changes occur in 
the epithelial transcriptome and to protein expression to mediate alterations in cell 
signaling and to support and maintain a new phenotypic identity, both in developmental 
and diseased settings (reviewed in [29, 31, 32]). 
Under normal physiological conditions, EMT is a tightly regulated molecular 
process. Interestingly, its regulation is highly dynamic. Extracellular signaling via the 
ECM, release of growth factors, activation of signaling cascades and transcription factors, 
cellular crosstalk, and epigenetic mechanisms together mediate EMT [33-35]. Disruption 








Gonzalez, D. M. and D. Medici (2014). Sci. Signal. 7(344): re8-re8. 
Figure 1.2. Signaling pathways associated with epithelial to mesenchymal transition (EMT) 
transcriptional regulation. Key signaling pathways that induce TGFβ, Wnt, PI3K, among others, induce 
expression of EMT-associated transcription factors (e.g. Snail 1/2, Twist, ZEB 1/2, and LEF1). These 
transcription factors, when activated suppress the expression of cell junction proteins (e.g. E-cadherin, 
claudins, ZO-1, and Occludin) and activate mesenchymal-specific transcriptional programs. Activity of the 
EMT-associated transcription factors is inhibited by the miR-200 family and GSK-3β. 
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For an epithelial-based primary tumor to metastasize, it must lose its epithelial 
characteristics and intravasate into the bloodstream to travel to a distant site for re- 
colonization. To do so, epithelium derived cancers hijack EMT regulatory pathways to 
promote a migratory phenotype for invasion and metastasis of distal organs. The exact 
molecular mechanisms at work to prevent EMT and maintain the normal epithelial 
phenotype are poorly understood. Therefore, it is critical to study the regulation and 
functions of EMT under normal and pathological contexts for mechanistic understanding 
of the development and maintenance of epithelium-based cancers. 
2.2. EMT subtypes 
 
The EMT has been categorized into three subtypes based of physiological 
relevance. The type 1 EMT, in combination with the mesenchymal-to-epithelial transition 
(MET), occurs during embryogenesis and organ development to form functionally 
distinct cell types and tissues [35]. After gastrulation and formation of the primitive 
streak, three distinct germ layers arise. These layers differentiate into all mature tissue 
types through rounds of EMT and MET, primarily regulated by canonical Wnt signaling 
[35]. Continuous rounds of EMT suggest that cells exist in a broad range of phenotypes 
between epithelial and mesenchymal endpoints, indicating partial EMT may occur under 
specific cellular contexts. Indeed, studies have shown expression of both epithelial and 
mesenchymal markers associated with EMT during wound healing and in response to 
chronic inflammation within the liver, kidneys, lungs, and intestines, resulting in fibrosis 
[35-37]. 
The type II EMT is associated with wound healing. During this process, cells that 
include macrophages and fibroblasts are recruited to the site of injury where they release 
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growth factors, such as TGF-β and chemokines, to stimulate EMT through a host of 
signaling mechanisms [33], resulting in tissue regeneration. Due to chronic inflammation 
associated with a variety of pathologies, this form of EMT can remain constitutively 
activated, resulting in detrimental organ fibrosis and adverse health consequences [35]. 
The third subtype of EMT is associated with tumorigenesis and progression of 
metastatic cancers. Acquiring a mesenchymal phenotype increases cancer cell plasticity 
and stemness, allowing for migration away from the primary tumor site, intravasation 
into the blood stream, and subsequent colonization of a distal metastatic site [29, 35]. 
Numerous studies, both in vivo and in vitro have established the EMT program as a driver 
for tumor progression. Accordingly, the transition to a mesenchymal phenotype has been 
associated with increased resistance to senescence and apoptotic signaling seen in 
metastatic disease [32]. It is likely that a combination of genetic, epigenetic, and 
environmental factors promotes signaling and molecular alterations associated with 
initiation of EMT. However, the precise mechanisms by which epithelial based cancers 
initiate EMT are poorly understood. 
2.3. EMT associated transcription factors, molecular signaling, and epigenetic 
mechanisms 
During EMT, epithelial gene expression patterns are downregulated, concomitant 
with activation of a mesenchymal-associated transcriptional program. Transcription 
factors that promote EMT include snail family zinc-finger binding transcription factors 
(Snail1 and Snail2), zinc finger E-box—binding homologs (ZEB1 and ZEB2), and twist 
basic helix-loop-helix transcription factor 1 (Twist). These regulatory proteins play 
important roles in repressing transcription of adhesion proteins such as E-cadherin, β- 
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catenin and occludins (Fig. 1.2), and activation of mesenchymal-associated genes, two 
critical steps in EMT initiation. Matrix metalopeptidases are released to promote ECM 
degradation, accompanied by cytoskeletal changes including the formation of 
lamellipodia and filopodia to facilitate cell motility and invasive properties. As cell 
junctions are disassembled, the expression of surface proteins changes, stress fibers form, 
and integrin clusters transition at the migratory front of the cell [33]. These changes 
support transitional plasticity and the ability to respond to a changing extracellular 
environment. Hallmark protein markers of EMT include replacement of the cell adhesion 
protein E-cadherin with the mesenchymal counterpart, N-cadherin; loss of tight junction 
proteins such as zona occludins; increased expression of fibronectin, fibroblast specific 
protein 1 (FSP-1), and α-smooth muscle actin; and exchange of type IV for type I 
collagen [33] (Fig. 1.3). Together, these changes result in dramatic cytoskeletal changes 
which support the acquirement of a mesenchymal phenotype and loss of epithelial 
function [35]. 
Molecular changes associated with EMT are induced and regulated by multiple 
signaling pathways. The most well-defined pathway is mediated by the TGF-β signaling, 
which functions through formation of a heterotrimeric receptor complex at the cell 
surface upon ligand binding. Cellular responses to TGF-β can progress in a manner either 
dependent or independent of the transcription factor complex mothers against 
decapentaplegic homologs (SMADs). Additional signaling pathways involved in EMT 
include Wnt, Notch, Hedgehog, and hypoxia (Fig. 1.3.) [33]. Hormones and growth 
factors (e.g. parathyroid hormone-like hormone (PTHLH), growth hormone (GH), 
epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin growth factor 
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Figure 1.3. Epithelial-to-mesenchymal transition (EMT) alters transcriptional programs and 
induces changes in extracellular matrix (ECM) and cytoskeletal components. Diagram 
highlights morphological changes associated with a cell transitioning from an epithelial to a 
mesenchymal phenotype. Defining features/characteristics and protein markers for each cell type 
are displayed beneath their respective images. Briefly, EMT-associated transcription factors 
promote suppression of proteins involved in tight and adherens junctions and desmosomes. 
Components of the extracellular matrix are exchanged (e.g, type IV for type I collagen and α6β4 
for β1 and β3 integrins). Similarly, expression of actin stress fibers is increased and lamellipodia 
and filipodia are formed, altering cytoskeletal characteristics. Together, these changes promote cell 
individualization and motility. 
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(IGF), and platelet derived growth factor (PDGF)) are also important drivers of EMT and 
function through induction of downstream receptor tyrosine kinase (RTK) signaling 
cascades [33, 38]. Crosstalk between these signaling pathways adds to EMT complexity, 
and promotes tissue- and microenvironment-specific control of the transition. 
Epigenetic mechanisms, defined as heritable patterns in gene expression that are 
independent of alterations in the primary DNA sequence, play an important role in 
regulation of cellular identity and maintenance. DNA methylation patterns, histone 
modifications, nucleosome remodeling, transcription factors, and non-coding RNAs work 
together to activate and repress gene expression under different biological conditions and 
contexts. Similarly, epigenetic modulators play critical roles in regulating EMT in 
conjunction with molecular changes that influence gene expression and cell signaling, 
adding yet another layer of complexity to the regulation of EMT. Epigenetic alterations 
associated with EMT include global DNA hypomethylation, hypermethylation of specific 
gene promoters essential for epithelial phenotype (e.g. E-cadherin), recruitment of 
repressive chromatin complexes (often mediated by transcription factors) to promote 
post-translational modifications of histones and transcriptional repression, and 
deregulation of micro RNAs (miRNA; e.g. the miR-200 family) [34, 39]. Dynamic gene 
expression profiles throughout EMT indicate epigenetic mechanisms are key regulators 
of genome accessibility for transcriptional machinery during the transition. Although 
significant advances have been made in understanding the regulation of EMT, many 
questions remain unanswered, including which epigenetic mechanisms ensure that 
epithelial cells retain their identity and phenotype throughout successive cell divisions. 
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CHAPTER 3: MITOTIC GENE BOOKMARKING 
3.1. Overview 
The eukaryotic cell cycle is a tightly regulated biological process, comprised of 
four functionally distinct phases. During the Gap 1 (G1) phase, cells synthesizes all the 
necessary components required for error-free replication of the complete genome which 
occurs in the Synthesis (S) phase, immediately following G1. During the Gap 2 (G2) 
phase, which occurs directly after S phase, stringently regulated molecular mechanisms 
ensure that all the machinery and protein complement are in place for equal division of 
the duplicated genome into two identical progeny cells during the Mitosis (M) phase. The 
M phase is characterized by drastic changes in the genome, (i.e., chromosomal 
condensation) as well as in cellular morphology (i.e., major reconfiguration of the 
cytoskeleton to ensure cytokinesis), and poses a unique challenge to cellular phenotype 
and fate determination. The mechanisms that mediate restoration of lineage specific 
transcriptional programs in progeny cells are poorly understood. 
During interphase, transcription factors dynamically associate with chromatin to 
modulate gene expression (Fig. 1.4). Historically, transcription levels are considered 
globally suppressed during mitosis, as transcriptional machinery is unable to access the 
condensed chromatin and dissociates from mitotic chromosomes [40-42]. Development 
of high-resolution biochemical and molecular techniques has allowed for in-depth 
examination of transcriptional regulation during mitosis. 
A recent study showed that mitotic cells maintain steady low levels of 
transcription [43]. Interestingly, this study provided evidence that transcription of specific 
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Figure 1.4. Organization and localization of transcription factors during interphase and 
mitosis. Transcription factors distribute broadly throughout the nucleus as punctate foci and some 
localize to the periphery of nucleoli in interphase cells. During mitosis, transcription factors face 
three distinct fates: 1) A subset of transcription factors is displaced from mitotic chromosomes and 
degraded; 2) Others are displaced but remain stable in the cytoplasm; and 3) A small subset of 
specific transcription factors remains bound to target gene on mitotic chromosomes; these 
transcription factors are described as “mitotic bookmarks”. Some mitotically retained transcription 
factors also localize with nucleolar organizing regions (NORs), the precursor to interphase nucleoli. 
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in proliferation and cell growth were expressed during mid to late mitosis, compared to 
genes involved in cell identity and lineage determination and commitment that were 
expressed directly as cells exited from late mitosis into early G1. These findings indicate 
that chromatin landscapes must be kept accessible to transcriptional machinery by 
epigenetic factors and modifications to maintain low levels of transcription throughout 
mitosis. Indeed, histone modifications, DNA methylation patterns, key components of 
RNA polymerase machinery, and lineage-specific transcription factors have been 
identified on mitotic chromosomes, together establishing a regulatory environment 
conducive to transcription (reviewed in [44, 45]). 
3.2. Mitotic retention of epigenetic modulators 
The observed retention of epigenetic modifiers and factors on mitotic 
chromosomes implicates the potential for phenotypic memory programs that extend 
beyond the influence of regulatory information encoded in DNA sequences. The concept 
of mitotic gene bookmarking – retention of phenotype-specific transcription factors, 
histone variants, and components of RNA Pol I and II transcriptional machinery on 
specific gene loci for immediate activation post mitosis to maintain a distinct cellular 
phenotype through successive cell divisions – was first suggested by Levens and 
colleagues in 1997 [46]. This group showed alterations to chromatin structure at gene loci 
that were immediately activated in cells exiting mitosis. Subsequent studies in the early 
2000s identified histone marks in promoter regions of mitotic cells indicative of active 
transcription [47, 48]. Additionally, proteins involved in the regulation of epigenetic 
modifications have been shown to associate with mitotic chromosomes at subsets of 
genes. These include members of the bromodomain and extra-terminal domain (BET) 
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family of proteins [49], histone methyltransferases [50], acetyltransferases [51], as well 
as components of RNA Polymerase transcriptional machineries including the upstream 
binding factor 1 (UBF1) [52, 53], and TATA binding protein (TBP) transcription factor 
[54]. In accordance with these observations, a recent study by the Tijan group showed 
that mitotic retention of TBP resulted in recruitment of RNA Pol II machinery to specific 
gene loci to mediate their expression upon mitotic exit [55]. Together, these studies 
implicate mitotic retention of specific epigenetic modulators and general transcriptional 
machinery components is essential for maintaining chromosomal landscapes necessary 
for transcription to occur during and directly following mitosis. 
Additional support for the concept of mitotic gene bookmarking is provided by 
the retention of multiple lineage-specific transcription factors on mitotic chromosomes, 
indicating a functional role of these proteins in maintaining cellular phenotype through 
cell divisions. Sequence-specific transcription factors including the osteoblastic master 
regulator RUNX2 [56], liver-related FOXA1 [57], muscle restricted MyoD [58], and 
GATA1 in hematopoietic cells [59] have been shown to act as essential mitotic 
bookmarks required for phenotypic maintenance. Mitotically retained transcription 
factors can localize either with RNA Pol I-transcribed genes in nuclear organizing 
regions (NOR) or with RNA Pol II-transcribed genes involved in differentiation and cell 
cycle control (Fig. 1.4). Some transcription factors (i.e. members of the Runt-related 
family of transcription factors) occupy both RNA Pol I and II-transcribed genes during 
mitosis [52, 56, 60, 61]. Importantly, mitotically retained transcription factors are 
equally partitioned into the progeny cells, further supporting their roles in regulation of 
target genes as cells enter G1 [62]. Interestingly, evidence is accruing that not all 
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mitotically retained transcription factors exhibit a functional role in phenotypic 
maintenance during mitosis. For example, a recent study demonstrated that the BRD4 
transcription factor, which was previously identified as a mitotic bookmark and is 
broadly retained on mitotic chromosomes [49, 63-67], is not a functional mitotic 
bookmark. Disruption of BRD4 DNA-binding does not directly compromise expression 
of genes bookmarked by BRD4 during mitosis in human erythroid cells [68]. The 
authors argue that in this case specific mitotic histone acetylation marks act as mitotic 
bookmarks for post mitotic gene re- activation in G1, indicating that other epigenetic 
regulators may influence phenotypic identity. Therefore, to determine the functional role 
of transcription factor mitotic bookmarks, it is essential to interrogate their function 
specifically in mitosis. Furthermore, as an epigenetic mechanism, mitotic gene 
bookmarking likely relies on a combination of epigenetic components, including variant 
histone modifications, DNA methylation patterns, transcription factors, and other 
components of transcriptional machinery. 
3.3. Mitotic gene bookmarking in cancer 
Due to the important role of mitotic gene bookmarking in both establishing and 
maintaining specific cell lineages, it is unsurprising that dysregulation of this epigenetic 
mechanism may lead to the acquisition of diseased phenotypes. Accumulating evidence 
suggests a protective role for mitotic gene bookmarking against diseases characterized by 
irregular cell growth [61, 69, 70]. Importantly, it has also been proposed that some 
cancers hijack mitotic bookmarking to promote and sustain their malignant growth 
(reviewed in [44]). These suggestions implicate mitotic gene bookmarking as a delicate 
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and dynamic epigenetic mechanism that may function to preserve and promote both 
normal and malignant phenotypes in a context-dependent manner. 
Members of the runt-related transcription factor (RUNX) family function as 
mitotic bookmarks and serve as master regulators of osteogenesis, hematopoiesis, 
neurogenesis, and gastrointestinal development [71]. In acute myelogenous leukemia 
(AML), the chromosomal translocation t(8;21) that results in fusion of RUNX1/AML1 
and MTG8/ETO genes and expression of the AML1-ETO fusion protein, is frequently 
observed clinically [61, 72]. This leukemogenic fusion protein blocks myeloid 
differentiation and increases proliferation potential of incompletely differentiated cells. 
The fusion protein retains the RUNX1/AML1 DNA-binding domain. However, the 
nuclear-matrix-targeting signal and transactivation domains are lost [73]. Interestingly, 
despite dramatic alterations to the protein structure, AML1-ETO acts as a mitotic 
bookmark [74]. However, the subset of target genes bound by the fusion protein during 
mitosis differs from that occupied by the wild-type RUNX1/AML1. AML1-ETO binds 
and activates rRNA genes and pro-proliferative genes while down-regulating genes 
required for myeloid differentiation, together promoting irregular cell growth and 
leukemogenesis [61, 72]. Similarly, the mixed lineage leukemia protein has also been 
shown to function as a pro-oncogenic mitotic bookmark [50]. It is unknown how many 
oncogenic transcription factors may promote and sustain malignant phenotypes by 
mitotic gene bookmarking. 
Together, evidence suggests that mitotic gene bookmarking functions in a context 
dependent manner, regulating physiological cell identity when operative in normal cells 
and promoting malignant phenotypes when operative in cancer cells. The differential 
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functions of mitotic gene bookmarking necessitate investigation in numerous cell and 
tumor types, posing a potential and novel opportunity for therapeutic intervention. 
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CHAPTER 4: THE RUNX1 TRANSCRIPTION FACTOR 
4.1. Overview of RUNX transcription factors 
The Runt-related transcription factor 1 (RUNX1) is a member of the RUNX 
protein family, which consists of RUNX1, RUNX2 and RUNX3 proteins. Members of 
the RUNX family of transcription factors are characterized by a highly conserved runt 
homology domain (RHD), which mediates sequence specific binding of RUNX proteins 
to cognate sites in the genome and derives its name from the Drosophila regulatory runt 
gene, involved in establishing embryo segmentation, sex determination, and 
neurogenesis. [75-77]. RUNX proteins play important roles in regulation of cellular 
proliferation and differentiation in a variety of mammalian cell types, each playing 
unique roles in distinct developmental processes. RUNX1 is essential for normal 
embryonic hematopoiesis and is the most frequent target of chromosomal translocations 
in AML [78, 79]. RUNX2 is a key regulator of osteoblast growth and differentiation, 
bone formation, and turnover (reviewed in [80]) and mutations in RUNX2 are associated 
with diseases of bone malformation (e.g. cleidocranial dysplasia) [81, 82]. RUNX3 plays 
an essential role in neuronal development [83]. Together, these observations indicate that 
RUNX proteins may serve as novel therapeutic targets across a host of human diseases 
and highlight the requirement for a deeper understanding of the specific roles they play in 
both normal and diseased cells. 
All RUNX proteins associate with the core-binding factor β (CBFβ) protein to 
form a heterodimeric transcription factor complex. This interaction occurs via the highly 
conserved, 128-amino acid RHD, located towards the N-terminal end of each RUNX 
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Figure 1.5. RUNX1 protein structure. Depiction of the human RUNX1 protein structure with DNA 
binding/CBFβ interaction and nuclear localization domains highlighted. Amino acid numbering indicates 
the relative positions of each domain within the protein structure. The RUNX1 DNA binding domain is 
evolutionarily conserved and binds to DNA in a sequence specific manner. Heterodimeric association of 
core binding factor β (CBFβ) with RUNX1 increases RUNX1 DNA binding affinity by several fold. The 
RUNX1 carboxy terminus mediates interactions with multiple co-regulatory proteins and contains 
several functional domains that include a transactivation domain, a repression domain, and a subnuclear 
targeting signal. 
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imparts a favorable conformational change in the RHD, stabilizing the RUNX-DNA 
interaction and enhancing its DNA binding affinity by at least 6-fold [87]. When bound 
by CBFβ, the RHD contacts both the major and minor grooves of double-stranded DNA 
via specialized loops and its C-terminal tail (Fig. 1.6) [88]. Recent studies have 
confirmed that CBFβ plays an essential role in stabilizing RUNX proteins [82, 87-89]. In 
addition to the RHD, RUNX proteins contain multiple function domains in the C- 
terminal half. These include a transactivating domain, an inhibitory domain, and a 
subnuclear targeting domain (Fig. 1.5). The transactivating domain is responsible for 
interactions with co-activator proteins, (e.g., p300/CREB binding protein (CBP) [90, 
91] and histone acetyltransferases), involved in regulation of cellular proliferation and
differentiation. The inhibitory domain interacts with repressive complexes and 
counteracts the functions of the transactivating domain [92]. The nuclear matrix targeting 
signal (NMTS) is essential for directing the transcription factor to subnuclear sites to 
mediate gene transcription [93]. All RUNX proteins also contain a C-terminal VWRPY 
domain that interacts with the groucho/transducin-like enhancer of split (TLE), which 
acts as a transcriptional co-repressor [94, 95]. Activity of RUNX proteins is also 
regulated by post-translational modifications [96-100]. Additional studies have shown 
that each of the RUNX proteins selectively interacts with other transcriptional regulators, 
suggesting that specific co-regulator interactions may dictate tissue-specific 
transcriptional activities of RUNX proteins [89, 101-104]. 
4.2. RUNX1 in hematopoiesis and related malignancies 
The RUNX1 gene is essential for normal embryonic hematopoiesis. Runx1 
deficient mice are embryonically lethal between embryonic days 12.5 and 13.5, due to 
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Figure 1.6. The RUNX1-CBFβ complex interacts with DNA via the conserved runt 
homology domain. DNA is shown in red and yellow. The CBFβ subunit, depicted in dark 
blue, dimerizes with the RUNX1 subunit, depicted in cyan. The RUNX1 βA’-B loop (red) and 
C-terminal end (blue) interact with the DNA major groove. The RUNX1 βE’-F loop (green)
interacts with the DNA minor groove.
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severe hemorrhaging along the central nervous system (CNS) [105]. Although RUNX1 is 
not essential for development of all hematopoietic progenitors, its role in hematopoietic 
stem cell (HSC) generation during embryogenesis and myeloid cell lineage determination 
and commitment is indisputable [106-110]. Based on the clear evidence that RUNX1 is 
critical for normal hematopoiesis, it is no surprise that dysregulation of RUNX1 is 
frequently observed in a variety of hematopoietic diseases. 
The RUNX1 gene is a common target of mutations and chromosomal 
translocations in an array of hematologic-related malignancies, most notably acute 
leukemias. Most RUNX1 mutations that lead to diseased phenotypes occur in the RHD 
and affect RUNX1 DNA-binding and transactivation [111]. RUNX1 translocations are 
the most common genomic abnormality observed in AML. The t(8;21) translocation that 
produces the RUNX1-ETO fusion protein presents in approximately 12% of all AML 
cases and 40% of cases diagnosed within the AML M2 subtype [112]. The t(12;21) 
translocation that produces TEL-RUNX1 is another common chromosomal translocation 
involving RUNX1 and is found in approximately 25% of adolescent pre-B cell acute 
lymphoblastic leukemia (ALL) cases [113]. The t(3;21) translocation is the third most 
common chromosomal translocation involving RUNX1 [114, 115]. This translocation is 
associated with cases of chronic myelogenous leukemia (CML) that present in the blast 
phase. Additional hematopoietic disorders and predispositions have been associated with 
mutations in RUNX1 (reviewed in [72]). The variety of hematopoietic malignancies that 
display abnormalities in differential branches of the adult hematopoietic tree further 
establishes RUNX1 as a critical hematopoietic regulator. 
4.3. RUNX1 in breast cancer 
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The mammalian mammary gland is a complex and dynamic organ, comprised of 
collecting ducts and tubes which together form a branching network [116, 117]. At the 
cellular level, the mammary gland consists of two distinct cell lineages: the luminal 
lineage, which consists of alveolar and ductal cells, and the basal lineage, which consists 
of myoepithelial cells [118]. During embryonic and adolescent maturation, the 
reproductive cycle, and pregnancy, the mammary duct undergoes dramatic morphological 
and functional changes [119]. As such, tight regulation of mammary gland development 
and growth is required to prevent irregular cellular differentiation and aberrant 
proliferation. 
RUNX1 has been established as an important regulator of mammalian mammary 
gland development and homeostasis [120]. Interestingly, RUNX1 displays a 
spatiotemporal expression pattern throughout the developmental stages of the mammary 
gland [121]. Expression profiles are higher in basal cells compared with luminal cells, 
and are almost completely lost in differentiated alveolar cells, likely to allow for milk 
production and excretion [122]. However, the remaining regulatory functions of RUNX1 
in mammary gland development are poorly understood. 
Recent studies have identified that dysregulation of RUNX1 is associated with 
human breast cancers. A 17-gene signature predictive of metastatic disease included 
decreased RUNX1 expression [123]. Many breast tumors express lower levels of 
RUNX1 than healthy breast tissues. Furthermore, mutations including point mutations, 
frame-shift mutations, and deletions have been identified in RUNX1 in human breast 
carcinomas [122, 124, 125]. Importantly, these mutations primarily occur in luminal 
subtypes. Most of these mutations occur within the RHD and affect RUNX1 
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DNA-binding, which may lead to loss of function and alter the expression of a subset of 
RUNX1 target genes. Mutations in CBFβ have also been identified in breast cancers 
[124], indicating that interplay between the two binding partners is likely critical for 
normal mammary homeostasis, growth, and phenotypic maintenance. Based on these 
observations, studies have sought to elucidate the functional role of RUNX1 in the 
mammary epithelium and as a result have produced seemingly contradictory and 
paradoxical results. 
Many studies investigating the function of RUNX1 in the normal mammary 
epithelium and luminal tumors have suggested that RUNX1 acts as a tumor suppressor. 
Indeed, loss-of-function mutations in RUNX1 have been identified in breast cancer, 
suggesting RUNX1 is a driver in breast cancer development [126, 127]. Loss of RUNX1 
in normal HER2 negative mammary epithelial cells results in upregulation of FOXO1 
and a hyperproliferative phenotype and altered cellular morphology [128]. Consistent 
with the important role of RUNX1 in estrogen signaling [129, 130], a study by van Bragt 
and colleagues showed that conditional knockout of RUNX1 results in a decreased ER 
positive luminal cell population. However, additional mutations to another known 
oncogene, such as TP53 or RB1, overcame this deficit and resulted in hyperproliferative 
ER+ luminal cells with the ability to promote tumor development [122]. Furthermore, 
mammary stem cells cannot differentiate into mature lobules or ducts without the 
presence of RUNX1 [120, 130]. Studies by our group have demonstrated that chronic 
loss of RUNX1 is sufficient to induce EMT in both normal mammary epithelial cells and 
cancer stem cells [131, 132]. Together, these results suggest that RUNX1 suppresses 
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cancer stem cells within the normal mammary epithelium and tumorigenesis, perhaps 
specifically in hormone receptor positive cell lineages. 
In addition to the proposed role of RUNX1 as a tumor suppressor, a recent study 
by Ferrari and colleagues showed a correlation between increased RUNX1 expression 
and poor patient prognosis in triple-negative breast cancer (TNBC) [133]. This 
correlation is supported by an in vivo study in which increased RUNX1 expression was 
correlated with advanced disease [134]. Furthermore, studies utilizing cell lines 
representative of TNBC, such as MDA-MB-231 cells, have shown that inhibition of 
RUNX1 decreases proliferative and migratory properties in vitro [135]. 
It is evident that RUNX1 plays an imperative role in mediating estrogen signaling 
[122, 129, 130]. Therefore, the seemingly paradoxical roles of RUNX1 as both a tumor 
suppressor and oncogene, may be attributed to hormone receptor status combined with 
disease stage and mutational status; and suggests RUNX1 plays a context-dependent role 
in the development of distinct breast cancer subtypes. Further studies are required to 
decipher the molecular mechanisms through which RUNX1 exerts its effects within the 
normal and diseased mammary epithelium. 
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CHAPTER 5: STUDY RATIONALE AND HYPOTHESIS 
RUNX1 is an essential regulator of physiological processes including 
development of the mammary gland. Mutations in RUNX1 and its heterodimeric partner 
CBFβ have been identified in breast tumors. Studies by our group and others have shown 
RUNX1 is required to maintain the normal mammary epithelial phenotype [122, 128, 
132]. Depletion of RUNX1 in normal mammary epithelial cells results in acquisition of 
mesenchymal characteristics directly correlated with TGFβ and Wnt signaling. The 
family of RUNX transcription factors have been identified as mitotically retained 
nuclear regulatory proteins in multiple cell lineages [62]. Directly relevant to the study 
reported in this dissertation, Joshua Rose, a previous graduate student, showed that 
RUNX1 is maintained on mitotic chromosomes throughout all topologically identifiable 
stages of mitosis in normal mammary epithelial cells and bookmarks genes involved in 
cellular growth, proliferation, and phenotypic identity. 
This dissertation addresses the hypothesis that the RUNX1-CBFβ 
transcription factor complex maintains the normal epithelial phenotype through 
mitotic occupancy and post-mitotic transcriptional regulation of target genes 
involved in proliferation, growth, and cell identity; disruption of the RUNX1-CBFβ 
interaction and mitotic gene bookmarking initiates EMT, an essential process 
involved in breast tumor initiation and progression. 
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RESULTS 
A small molecule inhibitor disrupts RUNX1-CBFβ association 
Each member of the RUNX family of transcription factors forms a heterodimeric 
complex with the binding partner CBFβ (Fig. 2.1A). This complex associates with DNA 
through the highly conserved RHD, as identified by validating biochemical assays [87] 
and determined by its crystal structure [136, 137]. Accordingly, it is predicted that 
RUNX and CBFβ proteins interact with DNA at a 1:1:1 stoichiometric ratio [88]. 
Studies investigating the kinetics of RUNX-DNA and RUNX-CBFβ-DNA interactions 
have shown that RUNX-CBFβ dimerization significantly increases RUNX- DNA 
affinity [88, 138]. In order to prevent formation of the heterodimeric transcription factor 
complex and interfere with the RUNX1-DNA interaction, a study by Illendula, et al. 
designed and synthesized a library of small molecule inhibitors of CBFβ based on the 
crystal structure of the RUNX1-CBFβ complex bound to DNA [139]. Determination of 
the pharmacophore, combined with further chemical modifications to increase efficacy 
and potency, resulted in synthesis of the active compound (AI-14-91) (Fig. 2.1B). An 
inactive, structurally analogous control compound (AI-4-88) was synthesized based on 
the same principles (Fig. 2.1B) [139]. The efficiency of AI-14-91 to disrupt RUNX1- 
CBFβ dimerization, compared to its synthetic analogs, was analyzed by RUNX1 and 
CBFβ co-immunoprecipitation, followed by Western blot analysis (Fig. 2.1C) in acute 
myeloid leukemia SEM cells. Six-hour treatment with AI-14-91 was determined to 
sufficiently inhibit RUNX1-CBFβ interaction and decrease RUNX association of target 
genes in vitro [139]. Based on these findings, the current study utilized AI-14-91 to 
examine the effects of disrupting the RUNX1-CBFβ interaction on the global 
transcriptome and lineage identity of mammary epithelial cells. Additionally, this 
molecular tool may be used in future studies in part to investigate the role of RUNX1
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Figure 2.1. Small molecule inhibitor of CBFβ prevents association of RUNX1-CBFβ heterodimer.
A) Crystal structure of RUNX1-CBFβ heterodimer interacting with DNA. B) Chemical structures of
active CBFβ inhibitor (AI-14-91) and its inactive control compound (AI-4-88). C) Top panel: Western
blots of RUNX1-CBFβ co-immunoprecipitants shows dissociation of CBFβ from RUNX1 after 10µM
CBFβ inhibitor treatment for 6 hours in acute myeloid leukemia SEM cells. AI-14-91 induces
significant RUNX1-CBFβ dissociation post 6-hour treatment. Bottom panel: Quantification of RUNX1
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mitotic gene bookmarking, an epigenetic mechanism that has been implicated in 
determining and sustaining cell fate through cell divisions, in the mammary epithelium. 
Disruption of the RUNX1-CBFβ interaction alters cell morphology and the 
mammary epithelial transcriptome to initiate EMT 
To experimentally address the global requirement of the RUNX1-CBFβ 
interaction to maintain the mammary epithelial transcriptome, we performed RNA- 
sequencing and confirmed our observations by Western blot. Actively proliferating 
MCF10A cells were treated with the active CBFβ inhibitor, AI-14-91, and its inactive 
control, AI-4- 88, to disrupt RUNX1 association of target genes. Cell morphology was 
monitored via phase contrast light microscopy. Consistent with the known functions of 
RUNX1 in mammary epithelial cells [122, 131, 132, 140], significant cell death was 
induced post 48 hours of treatment and surviving cells appeared to be acquiring a more 
mesenchymal-like morphology (Fig 2.2A). Based on these observations a long-term 
experiment was designed to investigate if long-term disruption of RUNX1-CBFβ 
interaction resulted in a more permanent morphologic/phenotypic change. MCF10A cells 
were treated with 20 µM AI-14-91 for five days. Due to the significant amount of 
apoptosis that occurred, these five days were termed the “crisis phase”. At day five of 
treatment, a small, morphologically distinct, sub-population (~10%) survived 
(Fig. 2.2B). The surviving sub-population at day five was recovered by culturing cells in 
inhibitor- free growth medium for seven days. This population was termed the “recovery 
phase”. Three to four days post medium replacement, the recovered population clearly 
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Figure 2.2. Disrupting RUNX1-CBFβ interaction in MCF10A cells leads to a transformed 
epithelial phenotype. A) Phase contrast microscopy images of MCF10A breast epithelial cells treated 
with AI-4-88 or A-14-91 for 48 hours at 20µM. Left panel – 20X magnification, right panel – 40X 
magnification. The outlined rectangle in the left panel is the resulting 40X magnification in the right 
panel. B) Top panel: Experimental schematic depicting treatment and harvest schedule for MCF10A 
cells. Cells were treated with 20µM AI-14-91 at approximately 40% confluency. Samples harvested 
at 24 and 48 hours were grouped together as “crisis”. After five days of AI-14-91 treatment, the 
remaining cells were allowed to recover for seven days in untreated, complete growth medium. 
Samples harvested four and seven days post medium change were grouped together as “recovery”. 
Bottom panel: Phase contrast microscopy images from Day 0 (pre-treatment), 1, and 2 (top – left, 























displayed a mesenchymal-like phenotype (Fig. 2.2B). These observations indicate that 
disruption of RUNX1-CBFβ interaction, and thereby association of RUNX1 with its 
target genes, is critical for epithelial cell survival as reflected by the significant loss of cell 
viability in MCF10A cells. Importantly, a subpopulation of cells can adapt to loss of 
RUNX1 function through acquisition of a transformed, mesenchymal-like phenotype. 
Because the RUNX1-CBFβ heterodimer is a potent transcriptional complex, 
transcriptome-wide changes associated with the observed morphological changes induced 
through disruption of the RUNX1-CBFβ interaction and subsequent disruption of 
RUNX1 DNA-binding were defined. RNA-sequencing (in triplicates) was performed on 
samples harvested from parental MCF10A cells, 24 and 48-hour crisis samples, and day 
four and seven recovery cells. Transcriptomic changes associated with the crisis phase 
implicated a response to severe cellular stress while the recovery transcriptome displayed 
changes indicative of re-establishment of immune and metabolic functions and 
proliferative properties (Fig. 2.4B, Fig 2.5C). 
To gain a basic understanding of the progression from a normal mammary 
epithelial phenotype to a mesenchymal-like phenotype, the altered epithelial 
transcriptome that resulted from disruption of the RUNX1-CBFβ interaction was 
analyzed by differential expression, comparing individual experimental conditions with 
each other across the time course and with untreated parental MCF10A cells. Principal 
component analysis showed distinct clustering of crisis and recovery phases (Fig. 2.3). 
Crisis timepoints were significantly separated from the recovery timepoints along 
principal component 1, indicating a large difference in gene expression between crisis and 
recovery transcriptomes, likely indicative of two distinct cell types. Although some 
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Figure 2.3. Principal component analysis reveals two distinct cellular subpopulations upon 
disruption of the RUNX1-CBFβ interaction. Principle component analysis between 24 and 48-hour 
crisis (24h and 48h, respectively) and day 4 and 7 recovery (D 4 and D7, respectively) time points. 
Principle component 1 (PC1) displays significant variance between crisis and recovery groups, likely 
indicating two distinct cell types based on transcriptional changes. Principle component 2 (PC2) shows 
approximately half the variance of PC1. However, the PC2 variance is likely skewed due to inconsistent 
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Figure 2.4. Differential expression and pathway analysis of the genome-wide transcriptome post 
disruption of the RUNX1-CBFβ interaction across a progressive time course shows activation of 
stress response mechanisms and induction of a mesenchymal-like phenotype. A) Expression heat 
map of three biological replicates (indicates by numbers below samples labels) of 24 and 48-hour 
crisis and Day 4 and 7 recovery time points. The parameter for DE inclusion was a p-value less than 
0.05 between time points. Expression profiles are reordered to reveal five clusters of genes that follow 
similar expression patterns across the time course. B) Table of hallmark biological pathways, 
generated by GSEA, that contain a significant number of genes identified within individual clusters. 















Estrogen Response Early 33 200 2.00x10-14
p53 Pathway 36 200 3.05x10-13
Estrogen Response Late 35 200 1.40x10-11
Fatty Acid Metabolism 30 158 4.86x10-11
Oxidative Phosphorylation 33 200 2.63x10-10
Epithelial Mesenchymal Transition 24 200 2.24x10-5
Cluster 2 
TNFα Signaling 25 200 1.54x10-11
p53 Pathway 22 200 2.94x10-9
Apoptosis 16 161 1.62x10-5
Mitotic Spindle 14 199 3.12x10-4
Cluster 3 
TNFα Signaling 90 200 4.77x10-66
Hypoxia 72 200 6.71x10-45
MTORC1 Signaling 55 200 8.41x10-28
Unfolded Protein Response 37 113 4.51x10-22
Apoptosis 42 161 1.32x10-20
p53 Pathway 43 200 1.24x10-17
Protein Secretion 30 96 1.59x10-17
Glycolysis 42 200 7.29x10-17
Cluster 4 
E2F Targets 106 200 1.84x10-101
G2M Checkpoint 102 200 2.44x10-95
MYC Targets 88 200 4.81x10-75
MTORC1 Signaling 61 200 5.82x10-40
Mitotic Spindle 51 199 1.83x10-30
Unfolded Protein Response 27 113 5.96x10-16
DNA Repair 19 150 7.09x10-7
Cluster 5 
E2F Targets 61 200 1.98x10-53
Oxidative Phosphorylation 31 200 2.82x10-18
MYC Targets 26 200 1.09x10-13
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Figure 2.5. Differential expression and pathway analysis of the genome-wide transcriptome between 
Crisis and Recovery phases following disruption of RUNX1-CBFβ interaction shows changes in key 
regulatory pathways involved in cell proliferation, metabolism, cell cycle control, estrogen response 
(ER), and EMT. A) Differential expression heatmap of three biological replicates (indicated by numbers 
beneath sample labels) of 24 and 4 8-hour crisis and Day 4 and 7 recovery timepoints normalized t o 
parental MCF10A control expression. Parameters for significant differential expression were base mean 
expression greater than five, absolute log2 fold change greater than one, and a p-value less than 0.05. B) 
Scatterplot of log2 fold change crisis verses log2 fold change recovery. Genes displaying the highest 
levels of differential expression between the two groups are labeled individually. Crisis and recovery 
groups show unique expression patterns. C) Table of overlapping hallmark biological pathways with crisis 
and recovery stage expression profilesdetermined by GSEA. Hallmarkgene setswereretrievedfrom 
MSigDB. Enrichment score magnitudes reflect the correlation of overlapping pathway genes with the 
experimental phenotype. Positive and negative enrichment scores indicate up o r down-regulation o f 
pathway related genes in the experimental phenotype, respectively. 
Hallmark Overlapping Gene Set Enrichment 
Gene Set Crisis DEGs Size Score 
UPR 16 113 0.52 
mTORC1 Signaling 35 200 0.50 
TNF Signaling  69 200 0.45 
Hypoxia 53 200 0.48 
Glycolysis 32 200 0.40 
Apoptosis 30 161 0.26 
EMT 28 200 0.22 
p53 Pathway 37 200 0.20 
Apical Junction  24 200 -0.20
ER Early 36 200 -0.21
ER Late 30 200 -0.39
Hallmark Overlapping Gene Set Enrichment 
Gene Set Recovery DEGs Size Score 
Hypoxia 15 200 0.42 
IFN Response 21 200 0.41 
EMT 15 200 0.40 
Complement 19 200 0.36 
TNF Signaling 27 161 0.34 
KRAS Signaling  22 200 0.20 
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outliers existed, none lay in clusters from the opposite phase. This variation is likely due 
to the nature of the experiment, where cells may respond to and recover from disruption 
of the RUNX1-CBFβ interaction at slightly variable rates due to other external influences. 
Reordering of mean expression across the time course revealed five distinct gene clusters 
(Fig. 2.4A). Pathways associated with each cluster were determined by gene set 
enrichment analysis (GSEA). Clusters one and two revealed pathways involved in 
hormone response, cell cycle regulation (i.e. p53 pathway), increased metabolic 
production (i.e. oxidative phosphorylation), inflammatory response (i.e. TNFα), and EMT 
(Fig. 2.4B). Together these pathways may act to establish and protect a mesenchymal-like 
phenotype as they are up-regulated throughout the time course. Clusters three and four 
show a generally decreasing trend, from high expression profiles to low expression 
profiles, between each timepoint. These clusters were shown to be predominantly 
involved in pathways related to increased levels of cellular stress (Fig. 2.4B), consistent 
with observed cell death at earlier time points. Furthermore, these pathways are associated 
with early changes in the epithelial transcriptome and help explain the large amounts of 
cell death observed. Of note, at the 48-hour timepoint, cluster three genes are upregulated. 
Here, genes involved in the mTORC1 pathway, critical for promotion of protein synthesis 
and cell growth, may be essential for synthesizing proteins needed to alter cell 
morphology throughout the transition. Importantly, the mTROC1 pathway has been 
implicated in breast cancer progression and as a therapeutic target [141, 142]. 
Additionally, these clusters are overlapped with the oncogenic pathway driven by the 
MYC transcription factor. As such, dysregulation of this pathway may promote cellular 
transformation, increased cell growth, and potentiallya more aggressive and invasive 
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phenotype. Cluster five was significantly smaller than the other four pathways. Its 
expression profile shows dynamic expression profiles between timepoints (Fig. 2.4B). 
Pathways associated with cluster five were involved in apoptosis and cell growth, 
metabolism, and hormone response, however, none are unique from the other four 
clusters. Together, these analyses reveal a novel finding: inhibition of the RUNX1-CBFβ 
complex results in an acute response at 24 and 48-hour timepoints that involves 
transcriptomic changes associated with downregulation of pathways critical for hormone 
response, cell growth, and proliferation, and upregulation of DNA repair mechanisms 
and apoptotic pathways, and a chronic response at day four and seven timepoints post 
medium change, when pathways associated with re-establishment of hormone signaling, 
cellular transformation, and cell cycle are predominantly activated. 
Differential expression (DE) analysis was performed between each of the two 
phases – crisis and recovery - and parental MCF10A cells. Heatmap analysis (Fig. 2.5A) 
showed significant changes in gene expression between both phases and parental 
MCF10A cells, indicating drastic changes in the epithelial transcriptome as the cells 
transition into a mesenchymal-like phenotype. A scatterplot of DE genes (base mean 
expression greater than five, log2 fold change greater than 1, and an adjusted p-value less 
than 0.05) displayed unique distributions of DE genes between crisis and recovery phases 
as predicted by the day-to-day analysis (Fig. 2.5B). Genes associated with EMT 
including IL32, PLOD2, and FGF2 were differentially expressed, among others, 
indicating that EMT induced through disruption of the RUNX1-CBFβ interaction and 
subsequent RUNX1-DNA binding (Fig. 2.5A/B) is driven by transcriptional activity of 
the complex. 
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GSEA pathway analysis was performed on differentially expressed genes in crisis 
and recovery phases (Fig 5C). Pathways identified were consistent with observed 
morphological changes. Crisis phase expression patterns were associated with pathways 
indicative of acute cellular stresses including irregular protein processing (e.g. unfolded 
protein response), hypoxia, inflammatory (i.e. TNFα), and hormone response (i.e 
estrogen response early/late), consistent with the analysis between timepoints. 
Importantly, estrogen response elements play vital roles in promoting proliferation in the 
mammary epithelium [143-145]. Despite the low estrogen receptor expression profile in 
MCF10A cells, downregulation of this pathway may lead to altered proliferative 
tendencies. Combined, these changes likely result in decreased cell viability and loss of 
phenotypic identity, resulting in induction of apoptosis, cell death, and EMT. 
Additionally, pathways such as mTORC1 and those involved in cell cycle regulation may 
be required for cellular transformation into the surviving subpopulation which displays an 
elongated, mesenchymal-like phenotype and maintains proliferative properties. These 
changes, relative to parental MCF10A cells, further indicate an acute response to loss of 
RUNX1-CBFβ association that may provoke initiation of EMT due to loss of RUNX1 
association with its target genes. Pathways associated with recovery expression profiles 
were more indicative of an altered, more established phenotype. Although pathways that 
respond to cellular stresses (i.e. hypoxia) were still present, cells were no longer 
undergoing rapid cell death. Alterations to genes involved in the oncogenic pathway 
regulated by MYC seen between timepoints (although not DE when compared to parental 
MCF10A cells) may act to prime cells for a transition to a more malignant phenotype. 
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Together, these observations indicate establishment of pro-oncogenic metabolic and 
immune responses required to promote proliferation of transformed cells. 
To functionally validate that decreased RUNX1-CBFβ interaction initiates EMT, 
we analyzed whole cell lysates throughout the entire time course by Western blot for 
protein markers indicative of EMT. Previous studies by our group have indicated that 
RUNX1 and RUNX2 display inverse expression profiles within the breast epithelium 
[146]. Western blots for RUNX1 show relatively constant protein levels across the time 
course (Fig. 2.6). Accordingly, RUNX2 protein levels remain low, indicating RUNX1 
protein levels are not immediately altered upon inhibition of CBFβ association, nor is 
RUNX2 expression induced as a potential compensation mechanism. Blots for the 
epithelial marker, E-cadherin, showed similar consistency of protein expression across 
the time course. Conversely, the mesenchymal marker, Vimentin, was starkly upregulated 
during the recovery phase (Fig. 2.6). Although many studies have used loss of E-cadherin 
and upregulation of Vimentin as definitive markers of EMT, the complexity of EMT 
regulatory mechanisms makes these observations alone neither definitive nor sufficient 
[147]. Although cells may not display significantly decreased levels of E-cadherin (as 
seen in this study), they may still become migratory due to weakened cell-cell 
interactions. Together, analysis of protein markers and transcriptomic changes, supports 
EMT in response to disruption of RUNX1-CBFβ interaction, consistent with the 
observed morphological changes in surviving cells. 
Disruption of the RUNX1-CBFβ interaction blocks the G1/S transition and 
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Figure 2.6. Long-term disruption of the RUNX1-CBFβ interaction changes expression of EMT- 
related proteins. A) Three biological replicates of Western blots for RUNX1 (48 kDa), RUNX2 (56 
kDa), epithelial marker E-cadherin, mesenchymal marker Vimentin, and loading control β-actin (top 
panels to bottom panels, respectively) in MCF10A whole cell lysates harvested from untreated parental 
MCF10A cells (P10A), 24-hour and 48-hour crisis timepoints (24 hr and 48 hr, respectively) and recovery 
day 4 and 7 timepoints (D 4 and D 7, respectively). Blots for Vimentin were not determined (N/D) in 
biological replicates 2 and 3 due to inconsistencies between antibody lots. Note that some specific 
proteins were blotted for on individual membranes. Internal controls were consistent between membranes 
within biological replicates. Therefore, only one internal control per biological replicate is show. Blots 
from individual membranes are represented with their correct internal control blots in Sup Fig 1. 
Exposure times for RUNX2 blots were significantly longer (~4x) those for all other antibodies. B) 
Quantification of antibody specific bands – RUNX1 (purple), RUNX2 (red), E-cadherin (green), and 
Vimentin (black) – across the time course. Band intensities were quantified using Image LabTM 
















Upon prolonged disruption of RUNX1-CBFβ the percentage of actively dividing 
(i.e. mitotic cells) was decreased. Fluorescence activated cell sorting analysis of 
asynchronous MCF10A cells for mitotic specific antibodies, H3pS10 and H3pS28, 
showed progressively decreasing mitotic populations post 24 and 48-hour AI-14-91 
treatments compared to inactive AI-4-88 control treatments (Fig. 2.7; Q2). Seventy-two- 
hour treatments unexpectedly did not show decreased mitotic populations. The H3S10 
residue is phosphorylated in late G2, whereas H3S28 is phosphorylated in prophase. 
Accordingly, a subset of cells was identified as H3pS10 positive and H3pS28 negative 
(Fig. 2.7, Q3), representing cells in late G2. Analysis of individual histone markers 
showed a larger percentage of cells to be positive for H3pS10 than H3pS28 (Suppl Fig. 
2). These observations align with respective mitotic spreads of each phosphorylation site. 
As previously observed, significant and progressive cell death was induced. As such, 48 
and 72-hour active compound counts were significantly less compared with their inactive 
counterparts. Variation in counts likely resulted in an overrepresentation of the mitotic 
population in these time points. This may explain the unusually high mitotic percentage 
observed after 72-hour active compound treatment. 
Analysis of DNA content across the time course showed a progressive decrease in 
G2 and S phase cells post 24 and 48-hour exposure to the active compound, compared 
with inactive controls (Fig. 2.8). Noticeably, G2 and S populations were also decreased 
post 72-hour inactive compound treatment. This is likely due to cell overcrowding as the 
culture reached confluence. Cell populations in both G2 and S phases continued to 
decrease post 72-hour active compound treatment compared to the 48-hour timepoint. 
Importantly, the sub-G1 population significantly expanded post 72-hour active compound 
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Figure 2.7. Prolonged disruption of the RUNX1-CBFβ interaction in MCF10A cells decreases the
mitotic population. Fluorescence activated cell sorting (FACS) analysis of asynchronous MCF10A 
populations labeled with a fluorophore conjugated H3pS28 specific antibody and a primary H3pS10 
specific antibody visualized with a fluorophore conjugated Alexa secondary antibody, to determine 
mitotic populations (n = 1 per group). Populations are ungated. Quadrant 1 (Q1) depicts H3pS28+, 
H3pS10- cells. Quadrant 2 (Q2) depicts H3pS28+, H3pS10+ cells. Quadrants 3 (Q3) depicts H3pS28-, 
H3pS10+ cells. Quadrant 4 (Q4) represents H3pS28-, H3pS10- cells (i.e. interphase cells). Numbers 
within each quadrant represent the population percentage located within individual quadrants. Top panel: 
MCF10A cells treated with 20µM inactive compound (AI-4-88) for 24 hours, 48 hours, and 72 hours, 
from left to right, respectively. Bottom panel: MCF10A cells treated with 20µM active compound 
(AI-14-91) for 24 hours, 48 hours, and 72 hours, from left to right, respectively. It is notable that event 
numbers vary between active and inactive compounds. This is likely due to the progressive increase in 
cell death observed with the active compound. Accordingly, antibody positive percentages may be 
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Figure 2.8. Prolonged disruption of the RUNX1-CBFβ interaction in MCF10A cells decreases G2 
and S populations. FACS analysis of asynchronous MCF10A populations stained with propidium iodide 
(PI) DNA dye (n = 1 per group). DNA content was used to determine cell cycle profiles. The top row 
represents MCF10A cells treated with 20µM inactive compound (AI-4-88) for 24 hours, 48 hours, and 72 
hours, from left to right, respectively. The bottom row depicts MCF10A cells treated with 20µM active 
compound (AI-14-91) for 24 hours, 48 hours, and 72 hours, from left to right, respectively. 
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treatment, likely representing cells undergoing apoptosis. Together, these observations 
indicate decreased cell viability and cycling in response to loss of RUNX1-CBFβ 
interaction, halting surviving cells in G1. Additional experiments are required to validate 
these observations. 
To further investigate the effects of disrupting the RUNX1-CBFβ interaction on 
the cell cycle expression of cell cycle regulatory proteins was analyzed by Western blot 
(Fig. 2.9). By 48 hours of CBFβ inhibition (48-hour crisis), protein levels of cyclin B1, a 
protein required for passage through the mitotic checkpoint, had significantly and 
reproducibly decreased (observed in all three biological replicates; Fig. 2.9). Similarly, 
levels of CDK2, required for progression through S phase, decreased throughout the 
crisis phase and into early recovery. This result was unexpected as CDK levels are 
generally stable throughout the cell cycle while cyclins are synthesized and degraded 
[148]. Levels for both proteins resurged in the recovery phase in accordance with the 
visibly proliferating transformed population. Together, these results further support a G1 
block in MCF10A cells that is induced by disruption of the RUNX1-CBFβ interaction. 
The p53 pathway is a key player in cell survival, stress response, and cell cycle 
progression [149, 150]. Genes involved in the p53 pathway were differentially expressed 
in RNA-seq analysis of the crisis phase, therefore, p53 proteins levels were further 
analyzed by Western blot to determine if p53 protein stability was compromised in 
response to disruption of the RUNX1-CBFβ regulatory complex. Individual membranes 
are displayed with their corresponding internal controls in Supp. Fig. 3. Decreased p53 
protein levels were observed at the 24-hour crisis timepoint (Fig. 2.9). Protein levels 
subsequently recovered across the remaining timepoints. These results were unexpected 
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Figure 2.9. Disruption of the RUNX1-CBFβ interaction alters expression of cell cycle regulators. A) 
Three biological replicates of Western blots for mitotic checkpoint regulators cyclin B1 and cyclin 
dependent kinase 2 (CDK2), DNA damage response element total p53, and internal control β-actin (top 
panels to bottom panels, respectively), in asynchronous MCF10A whole cell lysates harvested from 
parental MCF10A cells (P10A), 24-hour and 48-hour crisis timepoints (24 hr and 48 hr, respectively) and 
recovery day 4 and 7 timepoints (D 4 and D 7, respectively). Note that some specific proteins were 
blotted for on individual membranes. Internal controls were consistent between membranes within 
biological replicates. Blots from each membrane are represented with their correct internal control blot in 
Sup Fig 3. B) Quantification of antibody specific bands – cyclin B1 (green), CDK2 (purple), and total p53 
(red). Band intensities were measured in ImageJ. The mean intensities of proteins of interest were 
















when unbound from its inhibitor MDM2. Upregulation of these processes is expected in 
cells put under stress. These results suggest loss of RUNX1-CBFβ compromises p53 
protein stability in an acute setting. The p53 protein is able recover over time, however, it 
is unclear whether the recovering p53 helps induce apoptosis. The recovering p53 may be 
bound and inhibited by MDM2 or mutated and dysfunctional, aiding to promote cell 
proliferation and transformation. Additional experiments are needed to dissect this 
unusual observation and determine the mechanistic link between p53 and the RUNX1- 
CBFβ complex. 
RUNX1 organizes as punctate foci in the mammary epithelial cell nucleus during 
interphase and is dynamically redistributed during mitosis 
Previous studies have shown that RUNX proteins reside in punctate subnuclear 
domains and this subnuclear localization is functionally linked with transcriptional 
activity [103, 151-163]. To investigate subcellular localization of RUNX1 in normal 
mammary epithelial cells, a previous graduate student performed immunofluorescence 
(IF) [164, 165] microscopy in actively proliferating MCF10A cells and imaged cells in 
interphase as well as those undergoing spontaneous mitoses (Fig. 2.10)1. RUNX1 was 
distributed in punctate domains predominantly in the interphase nucleus; no cytoplasmic 
signal for the protein was detected above the slide background or when compared to cells 
immune-stained with only secondary antibodies (Fig. 2.10; top panel)1. Importantly, it 
was found that a subset of RUNX1 foci was localized on mitotic chromatin at all 
topologically identifiable substages of mitosis (Fig. 2.10; left column). Two distinct types 
1 A dissertation by Joshua T. Rose, entitled Maintenance of Mammary Epithelial Phenotype by 
Transcription Factor RUNX1 Through Mitotic Gene Bookmarking, completed in 2019 (ISSN: 2576-7550), 









































Figure modified from a dissertation by Joshua T. Rose, entitled 
“Maintenance of Mammary Epithelial Phenotype by Transcription Factor RUNX1 
Through Mitotic Gene Bookmarking”, completed in 2019 (ISSN: 2576-7550).
Figure 2.10. RUNX1 associates with DNA during interphase and remains bound to chromosomes 
throughout all stages of mitosis in fixed MCF10A cells. Representative immunofluorescence images of 
interphase and mitotic MCF10A fixed cells, acquired by confocal microscopy, showing subcellular 
localization of RUNX1, identified using a specific antibody, throughout mitosis. Mitotic cells were further 
classified into substages of mitosis based on DAPI topology. RUNX1 – Green (left column), DAPI – Blue 
(second column from left). Merged channel images (third column from left) contain an outlined region 
magnified in the right column labeled “inset”. White arrows highlight major Runx1 foci on mitotic 




of foci were detectable on mitotic chromosomes: 2-8 large punctate foci that appear to be 
allelic as well as numerous smaller foci that are distributed across the chromosomes (Fig. 
2.10; bottom panels, white arrowheads). Unlike the interphase nuclei, RUNX1 signal was 
also reproducibly detectable in the cytosol of prophase and metaphase cells, likely due to 
the absence of the nuclear membrane. The cytosolic RUNX1 signal was much less 
apparent in anaphase and telophase cells, coinciding with reforming of the nuclear 
membrane in progeny cells. This experiment was performed in triplicate and a minimum 
of 20 interphase and mitotic cells (inclusive of all substages) were imaged to ensure 
reproducibility. 
Because substantial cytosolic RUNX1 signal was observed in some stages of 
mitosis and multiple reports have indicated that formaldehyde fixation can prevent 
regulatory protein detection on mitotic chromosomes [55, 166], live cell microscopy was 
performed to confirm that association of RUNX1 with mitotic chromosomes is not under- 
represented as a result of formaldehyde fixation. The subcellular localization of RUNX1- 
EGFP was observed in actively proliferating, unfixed MCF10A cells. Multiple methods 
of transfection including lipid-based transfection and electroporation were employed to 
maximize delivery and expression of RUNX1-EGFP in spontaneously dividing MCF10A 
cells. Transfected cells were initially imaged continuously by wide-field microscopy, 
which permits imaging of live cells over longer periods of time without adversely 
affecting their viability. However, the images captured by this method were low 
resolution and RUNX1 foci present on mitotic chromosomes were not effectively 
captured (data not shown). To circumvent this issue, live cell images were captured using 
confocal microscopy. 
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Consistent with our findings in fixed cells, RUNX1-EGFP was associated with 
chromosomes in live MCF10A cells undergoing mitosis (Fig. 2.11). The RUNX1-EGFP 
distribution pattern throughout mitotic substages was analogous to previous observations. 
Prophase and anaphase cells displayed increased cytoplasmic RUNX1-EGFP signal, 
while the signal became nuclear specific in anaphase and telophase as the nuclear 
membrane began to reassemble. Together, these findings establish that RUNX1 foci are 
present on chromosomes at all stages of mitosis under physiological conditions in 
actively dividing, unfixed breast epithelial cells and, in agreement with our previous 
findings, are equally distributed into progeny cells [62]. Because mitotic association of 
RUNX1 has potential functional ramifications based on the actions of other cell lineage 
specific transcription factors and epigenetic markers during mitosis [43, 45, 50, 52, 56- 
62, 166-182], RUNX1 mitotic gene bookmarking was further investigated as a key 
epigenetic mechanism to maintain mammary epithelial cell identity. It was hypothesized 
that RUNX1 mitotic gene bookmarking is essential for coordinate control of target genes 
involved in cell proliferation and identity. 
Disruption of the RUNX1-CBFβ interaction dysregulates RNA Pol II-transcribed
genes bound by RUNX1 throughout mitosis. 
RUNX1 is dynamically redistributed during mitosis and a subset of RUNX1 foci 
localizes to mitotic chromatin, as determined by fluorescence microscopy (Fig. 2.11). To 
identify specific genes bound (or bookmarked) by RUNX1 during mitosis and in early 
G1, Joshua Rose, a previous graduate student, performed chromatin immunoprecipitation 
sequencing (ChIP-seq) in mitotically enriched MCF10A cells1. Peak calling identified 




















Figure 2.11. RUNX1 associates with chromosomes in live, unfixed, MCF10A cells during all stages 
of mitosis. Mammary epithelial MCF10A cells were transiently transfected with EGFP-RUNX1 and 
imaged by confocal microscopy without fixation (see Materials and Methods section for details). The left 
column shows RUNX1 (green) subcellular association with mitotic chromosomes in unfixed, live 
MCF10A cells. Cells were counterstained with Hoechst (middle column; blue) to visualize DNA in live 
cells and to identify mitotic cells and their respective substages. Merged images (bottom column) were 
generated to confirm localization of RUNX1 signal with DNA. Arrow heads indicate punctate RUNX1 
foci retained on mitotic chromosomes.
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Specifically, 551 genes (413 protein coding genes and 138 lncRNAs) were bound by 
RUNX1 within 5 kB of the transcription start site (TSS) during mitosis in mitotically 
enriched MCF10A cells, of which 378 genes overlapped with those occupied in early G1 
and 173 genes were only occupied during mitosis (Fig. 2.12A). Consistent with pathways 
affected by disruption of RUNX1-CBFβ interaction, GSEA analysis showed bookmarked 
genes were involved in gene expression, metabolic processes, G2M Checkpoint, E2F 
targets, p53, and DNA repair pathways (Fig. 2.12B). Importantly, one of the pathways 
identified was mTORC1 signaling, a pathway that is required for cell growth and is a 
therapeutic target in breast cancer [141, 142]. Relevant to the normal mammary epithelial 
phenotype, both early and late estrogen response gene sets significantly overlapped with 
RUNX1 mitotically bookmarked genes. These pathways further aligned with the known 
roles of RUNX1 [183-186]. 
To examine the functional relevance of RUNX1 occupancy of target genes during 
mitosis and early G2, differentially expressed crisis and recovery genes were compared to 
genes bookmarked by RUNX1 in mitosis. Based on the hypothesis that RUNX1 mitotic 
gene bookmarking is essential for coordinate control of target genes involved in cell 
proliferation and identity as cells transition from mitosis into early G1, we anticipate that 
disruption of this mechanism will quickly result in differential expression of bookmarked 
genes in asynchronous cells (e.g. in the crisis phase), concomitant with the observed 
epithelial to mesenchymal transition (Fig. 2-6). Of the RNA Pol II-transcribed genes 
bound by RUNX1 in mitotically enriched MCF10A cells within 5 kB, 23 were identified 
as DE in crisis phase and 4 were identified as DE in the recovery phase (Fig. 2.13A). 


















































Figure modified from a thesis by Joshua T. Rose, entitled 
“Maintenance of Mammary Epithelial Phenotype by Transcription Factor RUNX1 
Through Mitotic Gene Bookmarking”, completed in 2019.(ISSN: 2576-7550)
Figure 2.12. RUNX1 binds RNA Pol-II transcribed genes in asynchronous, mitotically 
enriched, and G1 MCF10A cell populations. A) Venn diagram depicts the number and overlap of 
RNA Pol II-transcribed genes, as determined by ChIP-Seq, bound by RUNX1 across asynchronous, 
mitotically enriched, and G1 populations. B) Table of overlapping hallmark biological pathways 
associated with RNA Pol-II transcribed genes bound by RUNX1 in mitosis within 5kb generated by 
GSEA. Hallmark data sets were retrieved from MSigDB. The top 10 overlapping pathways are 
displayed in order of statistical significance, from top to bottom.
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Figure 2.13. Disruption of RUNX1-CBFβ binding dysregulates RNA Pol II-transcribed genes 
bookmarked by RUNX1 during mitosis. A) Overlap of mitotically bound RUNX1 RNA Pol II-
transcribed genes with DE crisis and DE recovery genes. B) Log2 fold change of DE crisis and recovery 
RNA Pol II-transcribed genes bookmarked by RUNX1 in mitosis. From left to right, upregulated genes 
(purple) progressing to downregulated genes (black) in descending order. 
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genes were up-regulated in response to loss of RUNX1-CBFβ interaction, indicating that 
the complex primarily plays a transcriptional suppressive role in the crisis phase (Fig. 
2.13 B). Furthermore, significantly more RUNX1 bookmarked genes were DE during the 
crisis phase, which represents an acute response to disruption of the RUNX1-CBFβ 
interaction and the subsequent decrease in RUNX1 DNA-binding and mitotic occupancy. 
Notably, most DE mitotically bookmarked genes were also bound by RUNX1 during 
early G1, likely to re-establish the epithelial transcriptional program in newly formed 
progeny cells. However, a small subset of DE crisis bookmarked genes were exclusively 
bound by RUNX1 during mitosis (Table 1). Multiple biologically relevant genes were 
identified within the overlapping bookmarked DE crisis and recovery genes. 
Underscoring the biological relevance of these findings, Jagged1 (JAG1), a ligand 
involved in Notch signaling that is associated with increased therapeutic resistance and 
poor outcome in breast cancer [164, 187], was mitotically bookmarked by RUNX1 and 
significantly upregulated in the crisis phase. Similarly, TUBB3, a member of the tubulin 
family that has been linked to an aggressive breast cancer phenotype and modulation of 
EMT-related transcription factors such as SNAIL [188], and LAMB3, which encodes the 
beta 3 subunit of laminin and has been implicated in increased invasive and metastatic 
properties in a variety of epithelial-based cancers [165, 189, 190], fell into the same 
overlapping category. The lncRNA MALAT1, which is often dysregulated in breast 
cancer and has been shown to promote EMT [191, 192] was significantly upregulated 
during the recovery phase and bookmarked by RUNX1 during mitosis. Together, these 
results solidify the biological relevance of our findings and indicate that inhibition of the 
RUNX1-CBFβ interaction disrupts RUNX1 mitotic gene bookmarking, a potential 
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Crisis Recovery 
M / G1 M only G1 only M / G1 M only G1 Only 
ALDH3B1 HSPA5 PRSS22 MALAT1 ---- KRT18 
KLF6 ATP2B4 YBX2 CCDC9 MTUS1 
ASNS BIRC2 PGM3 RNF145 BLOC1S1 
NFKB2 SDCBP2 TNC RHOBTB3 PCDH7 
PPP1R15A RAP2B CD82 F2R 
FTL C1GALT1 CSF1R 
FKBP5 DKK1 GPC6 
JAG1 PPIF DIO2 
































Table 1. Overlap of differentially expressed crisis and recovery genes with genes bound by 
RUNX1 in mitosis and early G1 within 5 kB. 
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epigenetic mechanism to maintain mammary epithelial cell homeostasis and phenotype 
throughout successive cell divisions. The remaining section of this study seeks to identify 
the functionality of this mechanism. 
Experimental design and optimization to address the requirement of RUNX1 
mitotic gene bookmarking for maintenance of the mammary epithelial phenotype 
To establish the role of RUNX1 mitotic gene bookmarking in maintaining the 
mammary epithelial phenotype, the following experimental design requirements must be 
met: 
1. Efficient synchronize of cells in order to maximize mitotic enrichment.
2. Capture and analysis of only nascently transcribed RNA as cells progress
through mitosis into early G1 to rule out contribution of transcripts that are
inherited from the previous cell cycle, into the next; and
3. Specific and selective disruption of RUNX1 function (either by rapid
depletion or by interference with RUNX1-DNA binding) at mitosis to
eliminate the effects of RUNX1 regulatory functions during the rest of the cell
cycle.
Accordingly, an experimental strategy was designed to address the function of 
RUNX1-CBFβ occupancy of target genes throughout mitosis to maintain the normal 
mammary epithelial phenotype (Fig. 2.14). MCF10A cells were synchronized at the G2/
M transition using two independent methods. A small molecule inhibitor of RUNX1-
CBFβ may be used to disrupt RUNX1-DNA binding as cells were released through
mitosis and into early G1. Precision nuclear run-on (PRO) was employed to capture 
nascent RNA transcripts using biotin-labelled nucleotides followed by 
61 
MCF10A cells 





Late G2 synchronized cells 
Release 
Mitotic & G1 cells 
RNA isolation 






Figure 2.14. Experimental schematic to address functional relevance of RUNX1 mitotic gene 
bookmarking. MCF10A cells are treated with 9µM RO-3306 (a CDK1 inhibitor) for 20 hours to 
synchronize cells at the G2/M transition. 6 hours prior to end of synchronization, 20µM AI-14-91 is 
added to disrupt RUNX1-CBFβ binding, thereby disrupting RUNX1 mitotic occupancy. Cells are 
released into early G1. Nascent RNA transcripts from mitotic and early G1 cells are isolated by biotin 
run-on and pulldown using streptavidin beads. cDNA synthesis followed qPCR or RNA-Seq analysis of 
nascent transcripts is used to analyze expression patterns of RUNX1 mitotically bookmarked genes. 
62 
streptavidin bead-mediated purification. Expression analysis of nascent transcripts of 
genes bookmarked by RUNX1 in mitosis and involved in phenotypic maintenance and 
lineage determination, can then be performed either by qPCR or by RNA-sequencing. 
Successful implementation of this experimental strategy will establish the role of 
RUNX1 transcriptional regulation specifically during mitosis in order to maintain the 
mammary epithelial phenotype throughout successive cell divisions. 
I. Efficient synchronization of MCF10A cells to maximize mitotic enrichment
To synchronize cells in mitosis, MCF10A cells were initially treated with 
nocodazole (50 ng/µL) for 16 hours. Nocodazole dose and treatment were empirically 
determined to minimize toxic effects of the drug, while maximizing mitotic enrichment. 
Mitotic cells were collected by mitotic shake-off and purity of harvested cells was 
confirmed by the presence of H3pS28 in >70% of cells. The H3pS28 mark was chosen to 
determine mitotic cells because this histone mark is highly specific to condensed 
chromosomes during mitosis; the most commonly used H3pS10 mark is additionally 
observed in late G2 and early G1 cells and has also been associated with replicating 
centers in S-phase [193-195]. A parallel, nocodazole-treated cell population was released 
into early G1 by replacing nocodazole-containing growth medium with fresh, 
nocodazole-free, growth medium and was harvested 3 hours post-release (Fig. 2.15A). 
Western blot analysis of whole cell lysates from the three cell populations showed 
expected levels of expression for cell cycle-stage proteins Cyclin B and CDT1 (Fig. 
2.15B). Cell cycle profiles determined by FACS confirmed the characteristic enrichment 
of blocked cells in mitosis (Fig. 2.15C; Mitotic) and release into G1 upon media 
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Figure 2.15. Nocodazole induced mitotic synchronization of MCF10A cells and release into early 
G1. A) Experimental schematic depicting mitotic arrest and harvest of each treated MCF10A population: 
Asynchronous – A, Mitotic – M, and Released – G1. B) Western blot of each harvested MCF10A 
population for cell cycle specific markers to evaluate mitotic arrest and synchronization procedure. C) 
FACS analysis of harvested asynchronous, mitotically enriched, and G1 MCF10A populations labelled 
with a fluorophore conjugated H3pS28 antibody to determine mitotic purity and PI stain to determine 
DNA content and cell cycle populations (n=2 biological replicates per group). Mitotically enriched cells 
were physically shaken-off and harvested (see methods for details). The G1 population was synchronized 
identically to the mitotically enriched population, nocodazole-treated media was removed, and cells were 


























Asynch). Although most cells released into early G1, the mitotically enriched population 
was <80% and >25% of the population remained in G2 post 3-hour release. Additionally, 
a subpopulation of cells remained visibly asynchronous in the blocked population directly 
prior to release. 
To increase the purity of the released population, blocked cells were collected by 
mitotic shake-off, re-plated in fresh growth medium, and allowed to release for three 
hours for entry into early G1. Upon harvest, a large population of released cells had yet to 
adhere to the surface of the culture plate and regain their phenotype. Many of these cells 
appeared unhealthy. FACS profiles of the cell populations showed poor release from 
mitosis into G1 (Fig. 2.16; G1). These data indicate mitotically shaken-off MCF10A cells 
do not readily re-adhere nor progress through the cell cycle and may have compromised 
health and viability. 
To further investigate the viability of nocodazole-treated cells, an Annexin V 
assay was performed to evaluate apoptotic and necrotic cells. An increased population of 
necrotic cells were identified in the mitotically enriched population compared to the 
asynchronous population (Fig. 2.17; mitotic). Similarly, the released (without shake-off) 
population showed an increased proportion of early and late apoptotic and necrotic cells 
compared with the asynchronous population (Fig. 2.17; G1). These findings are 
consistent with known deleterious effects of nocodazole and indicate that exposure to 
nocodazole mildly impairs cell viability [196, 197]. However, additional replicates are 
required to confirm these results. Together, these observations suggested that nocodazole 
synchrony does not meet the purity of mitotic enrichment or viability of cells necessary to 
establish mitosis-specific transcriptional activity of RUNX1. 
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Figure 2.16. MCF10A cells remain enriched in G2/M using the shake-off procedure to release cells 
into early G1. FACS analysis of harvested asynchronous, mitotically enriched, and G1 MCF10A 
populations stained with PI to determine DNA content and cell cycle populations. Mitotically enriched 
cells were physically shaken-off and harvested. The G1 population was physically shaken-off, re-plated 
and released for three hours in nocodazole-free, complete growth medium for three hours. Each 
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Figure 2.17. Nocodazole induced mitotic synchronization results in mild but progressive cell death 
in mitotically enriched and G1 populations. FACs analysis of Annexin V assay to determine cell 
viability in harvested asynchronous, mitotically enriched, and G1 MCF10A populations (n = 1 biological 
replicate). Mitotically enriched population was physically shaken-off and harvested. The G1population 
was synchronized identically to the mitotically enriched population, then released in nocodazole-free, 
complete growth medium for three hours. A 7- AAD stain was used to identify DNA content. 7-AAD 
combined with Annexin Cy5 allows for determination of stages of apoptosis or necrosis. Quadrant 4 (Q4) 
depicts normally proliferating cells. Quadrant 3 (Q3) depicts early apoptosis. Quadrant 2 (Q2) depicts late 












































A study by Vassilev, and colleagues identified a selective and reversible inhibitor, 
RO-3306, of human CDK1/cyclin A and CDK1/cyclin B1 complexes and their catalytic 
activities [198]. Inhibition of CDK1 mediated complexes allows for synchronization of 
actively proliferating cells in late G2 (Fig. 2.18A). For investigating the role of RUNX1 
mitotic gene bookmarking, halting cells in late G2 is preferable to nocodazole induced 
synchronization which blocks cells during prometaphase/metaphase and releasing cells 
from late G2 allows for analysis of transcriptomic changes that may occur throughout all 
stages of mitosis. 
Conditions for RO-3306 mediated late G2 synchronization were optimized in 
MCF10A cells. Cells were treated with 9 µM RO-3306 for 20 hours. Post treatment, cells 
had obtained a noticeable rounder morphology, but had not formed condensed spheres as 
was observed post nocodazole treatments (Fig. 2.18B; Blocked) compared with the 
DMSO control (Fig. 2.18B; DMSO). When released, chromosomes were visibly 
condensed, and cells progressed through mitosis in approximately one hour and were 
established in G1 after three hours (Fig. 2.18B; bottom panel). FACS profiles showed 
that approximately 90% of single, live cells were blocked in late G2 (Fig. 2.18C; G2/M) 
and most cells had progressed into G1 after the three-hour release (Fig. 2.18C; G1). 
Minimal cell death was observed in blocked and G1 cell populations, indicating minimal 
toxic effects induced by the 9 µM dosage. These analyses establish RO-3306 induced cell 
synchronization as an effective tool for mitotic specific transcriptomic analysis. Future 
studies are needed to determine whether RO-3306 induces any apoptosis and to further 
validate minimal effects of the CDK1 inhibitor on cell viability. 
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Figure 2.18. The CDK1 inhibitor RO-3306 synchronizes MCF10A cells in late G2 and allows for 
efficient releases of cells into mitosis and early G1. A) Depiction of the RO-3306 chemical structure 
and its effect on the cell cycle (phases of the cell cycle are not to scale). B) Phase contrast microscopy 
images of MCF10A cells in culture throughout G2/M synchronization and early G1 release. Cells were 
treated with 9µM RO-3306 for 20 hours and released for 3 hours in untreated, complete growth medium. 
Top panel: pre-treatment, DMSO control, and blocked populations (left to right, respectively). Bottom 
panel: 15-minute release, 45-minute release, and 3-hour release populations (left to right, respectively). 
C) FACS analysis of harvested asynchronous, G2/M, and G1 populations stained with PI DNA stain.
DNA content was used to determine cell cycle populations and efficiency of RO-3306 induced block and





















To optimize enrichment of nascent transcripts, biotin nuclear run-on was 
performed through incorporation of biotin-labelled nucleoside triphosphates (NTPs) by 
RNA polymerases into the nascent transcripts. Incorporation of a biotin-labelled NTP 
inhibits further incorporation of addition biotin-labelled NTPs, resulting in RNA 
polymerase mapping with base-pair resolution. To determine the success of the precision 
nuclear run-on strategy, actively proliferating MCF10A cells were treated with 
Actinomycin D (1 µg/mL) for six hours to reduce global transcription levels. 
Actinomycin D is a potent, weakly reversible, inhibitor of all three eukaryotic RNA 
polymerases, effectively inhibiting transcription [199]. Actinomycin D treated cells 
displayed noticeably disrupted nucleoli (Fig. 2.19A; 6 Hour Act-D) compared with the 
DMSO control (Fig. 2.19A; DMSO). Nascent transcripts were isolated from actinomycin 
or DMSO treated asynchronous MCF10A cells by biotin nuclear run on and streptavidin 
bead-mediated capture/enrichment. qPCR of enriched nascent transcripts for protein 
coding genes (GAPDH, CDH1, and RUNX1) and the ribosomal RNA precursor (pre-
rRNA) showed decreased expression (increased CT values) in actinomycin D treated 
MCF10A cells (Fig. 2.19B) compared with DMSO controls. These results indicate 
successful enrichment and amplification of nascent transcripts and validate this 
procedure for transcriptomic analysis of nascent RNA in MCF10A cells. 
III. Specific and selective disruption of RUNX1 function at mitosis
Future studies using the aformentioned optimized experimental conditions are 
required to examine the role of RUNX1 mitotic gene bookmarking in maintaining the 
normal mammary epithelial phenotype. These studies will additionally require precision 
genome editing to develop an MCF10A derived cell line in which the endogenous 
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Figure 2.19. Optimization of nascent RNA pulldown. A) Phase contrast microscopy images of 
MCF10A cells in culture treated with either DMSO or 1 µg/mL Actinomycin D for 6 hours (left to right, 
respectively). Actinomycin D served as a control to decrease global transcription levels to validate the 
functionality of the nascent pulldown of biotinylated RNA in MCF10A cells. B) qPCR amplification plots 
of RNA Pol-I and II transcribed genes from DMSO and Actinomycin D treated nascent RNA. The cycle 
threshold (CT) indicates the number of PCR cycles required to amplify the gene of interest beyond 
background levels. Higher CT values correspond to lower expression profiles. 
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RUNX1 has been tagged for rapid and inducible degradation. This cell line will allow for 
investigation of mitosis-specific transcriptional role of RUNX1 in maintaining the 
mammary epithelial phenotype. RUNX1 degradation in mitosis will be coupled to biotin 
nuclear run on in mitotically enriched and G1 cells followed by qPCR (PRO-qPCR) and/
or RNA- sequencing (PRO-seq) to identify transcriptomic changes that result from loss 
of mitotic RUNX1 occupancy and regulation of target genes as cells divide. Preliminary 
experiments utilizing the small molecule inhibitor of CBFβ (AI-14-91) to disrupt 
RUNX1-DNA in mitotically enriched cells coupled with PRO-qPCR may be performed 
to gather further evidence of the functional role of RUNX1 mitotic gene bookmarking to 
support investment in PRO-seq with inducible RUNX1 degradation. 
Immunoprecipitation experiments in MCF10A cells are required to optimize the inhibitor 
treatment time needed to effectively disrupt the RUNX1-CBFβ interaction and 
subsequent RUNX1 DNA-binding. Finally, because RUNX1 mutations have been most 
frequently identified in ER+ breast cancers, and MCF10A cells are ER receptor low, 
parallel studies should be performed in ER-positive cell lines to further validate the role 
of RUNX1 mitotic gene bookmarking in maintaining the normal mammary epithelial 
phenotype. However, obtaining and maintaining ER+ normal mammary epithelial cell 
lines remains a major challenge in the field. 
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DISCUSSION 
This study establishes that pharmacological disruption of the RUNX1-CBFβ 
transcription factor complex perturbs mammary epithelial homeostasis and results in 
transition of epithelial cells to a mesenchymal-like phenotype. Building on observations 
by Joshua Rose, this study confirms that RUNX1 interacts with mitotic chromosomes 
during all topologically identifiable stages of mitosis, and optimizes conditions to 
interrogate specific functions of the RUNX1-CBFβ complex as a mitotic bookmark for 
coordinate control of mitotic and post-mitotic regulation of target gene expression 
necessary for epithelial cell growth, proliferation, and phenotype. 
Inhibition of the RUNX1-CBFβ interaction disrupts the normal mammary epithelial 
phenotype and initiates EMT 
The dramatic change in cellular morphology and function observed upon 
disruption of the RUNX1-CBFβ interaction (Fig. 2.2) suggests that the transcription 
factor complex is critical for regulation of essential genes required for establishment and 
maintenance of the normal mammary epithelial phenotype. Disruption of the RUNX1- 
CBFβ complex resulted in transcriptional changes of genes related to pathways involved 
in cell cycle control, DNA repair, cell growth, cell junctions, and estrogen response. 
These observations are consistent with reports that CBFβ stabilizes RUNX1 DNA- 
binding in a variety of cell types and developmental processes [82, 87-89], and that loss 
of RUNX1 function in the normal mammary epithelium results in a hyperproliferative 
phenotype and altered cellular morphology [128]. This study, for the first time, shows 
that the interaction between RUNX1 and its binding partner CBFβ is required for normal 
73 
mammary epithelial phenotype and highlights, at least in part, a mechanistic explanation 
for how RUNX1 functions to maintain normal mammary epithelial cell identity and 
homeostasis. 
An important finding from this study, relates to the potential role of the RUNX1- 
CBFβ complex in the regulation of estrogen response in breast cancer. Although this 
study was performed in ER low MCF10A cells, disruption of the RUNX1-CBFβ 
interaction dysregulated ER signaling. These results are congruent with reports that 
RUNX1 interacts with ERα at both enhancer regions and transcriptional start sites, 
playing an essential role in regulation of estrogen signaling [122, 129, 130]. Furthermore, 
these results suggest that despite low ER expression in MCF10A cells, the RUNX1- 
CBFβ transcription factor complex is an essential regulator of ER response, a key 
pathway involved in maintenance of the normal mammary epithelial phenotype. Because 
RUNX1 plays an important role in estrogen signaling and is most frequently mutated in 
ER+ breast tumors, studies examining roles of the RUNX1-CBFβ transcription factor 
complex in ER+ mammary epithelial cells will uncover clinical significance of the 
interplay between the two regulatory pathways. 
In addition to the role in estrogen signaling, disruption of the RUNX1-CBFβ 
complex had a profound effect on the expression of genes related to the p53 and TNFα 
pathways. A study by Wu and colleagues showed that RUNX1, in fact, regulates the p53 
pathway, specifically in response to DNA damage [184]. Interestingly, upregulation of 
genes involved in p53 signaling were observed in the crisis phase; concomitantly with a 
significant increase in apoptosis. Consistent with these findings, 10 of the 37 
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differentially expressed crisis genes involved in the p53 pathway overlapped with genes 
involved in apoptosis. Importantly, dysregulation of the p53 pathway may also contribute 
to uncontrolled cell growth and EMT. Genes associated with the TNFα pathway, that is 
also known to induce apoptosis in epithelial cells placed under stress [200, 201], were 
significantly upregulated during the crisis phase. Furthermore, TNFα signaling and other 
inflammatory mediators have been shown to induce and enhance EMT in other tumor 
models [202-204]. Together, these results indicate that disruption of the RUNX1-CBFβ 
interaction upregulates TNFα and p53-mediated signaling which may drive programmed 
cell death during crisis while simultaneously promoting EMT in the small subpopulation 
of surviving cells. Notably, the p53 pathway is no longer dysregulated during recovery. 
This observation may suggest that the transformed mesenchyme-like cells either contain 
a mutated version of p53 which promotes growth and the mesenchymal phenotype or 
have acquired additional mutation that functionally decouple the RUNX1-p53 pathways. 
These hypotheses can be experimentally tested using genetically engineered mammary 
epithelial cells with inducible deletion of one or both proteins. An alternate possibility is 
that because the recovery cells were cultured in the absence of the pharmacological 
inhibitor, the RUNX1-CBFβ complex regained its functional properties and resumed its 
regulatory interplay with the p53 pathway. This hypothesis can be experimentally 
addressed by treating recovery cells with the pharmacological inhibitor and assessing 
effects on the p53 pathway and apoptosis. 
A recent study by Malik and colleagues showed that CBFβ plays an important 
role in orchestration of translation of many proteins including RUNX1. This regulation is 
imparted through direct interaction of CBFβ with RUNX1 mRNA in conjunction with 
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hnRNPK, a protein involved in pre-mRNA processing [205]. Importantly, CBFβ interacts 
with hnRNPK and the RUNX1 RHD via the same binding domain [88, 205], implying 
that CBFβ inhibition by the pharmacologic inhibitor used in this study, may affect both 
the nuclear and cytoplasmic functions of CBFβ. Complete depletion of CBFβ results in 
loss of RUNX1 protein expression. However, in this study, no significant decrease in 
RUNX1 protein was observed. This observation can be explained through two lines of 
reasoning: first, the congruent loss of RUNX1 protein expression upon depletion of 
CBFβ, as observed by Malik and colleagues, is likely the result of prolonged depletion 
and selection of CBFβ-null cells. The results presented in this study are representative of 
an acute loss of CBFβ function, therefore, sufficient time may not have elapsed for us to 
observe alterations to the mRNA processing/translational functions of CBFβ. Secondly, 
the pharmacological inhibitor used in this study may selectively disrupt the RUNX1- 
CBFβ-DNA interaction and therefore, impart minimal effects on the translational 
functions of CBFβ. Further studies are required to determine the specific effects the 
pharmacologic inhibitor of CBFβ has on protein translation in MCF10A cells. 
Accordingly, findings reported in this dissertation cannot rule out the possibility that 
other cytoplasmic functions of CBFβ may be impaired in this study and may influence 
the observed phenotypic transition. 
Pharmacological disruption of the RUNX1-CBFβ interaction and decreased RUNX1 
DNA-binding identifies acute versus chronic gene regulatory responses 
Studies by our group and others have shown that long-term depletion of RUNX1 
results in EMT and breast cancer initiation [122, 132, 205]. This study presents a novel 
finding, i.e., short-term disruption of RUNX1 DNA-binding is sufficient to elicit an 
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EMT. Experimental conditions used in this study clearly depict two distinct crisis and 
recovery phases: a crisis phase, characterized by wide-spread apoptosis and cell death 
and a recovery phase, characterized by a distinct morphological change in surviving cells. 
During the crisis phase, significant cell death is induced while a small subpopulation of 
cells undergoes EMT, transforming its transcriptional program to promote survival and 
proliferation with newly acquired mesenchymal characteristics. This subpopulation 
colonizes and expands during the recovery phase. Accordingly, cells in crisis are either 
actively undergoing programmed cell death or are in transition; while cells in recovery 
are definitively transformed and display what is likely a similar phenotype to RUNX1 
depleted cells. 
Transcriptomic analysis of crisis and recovery phases revealed distinct 
transcriptional profiles, further highlighting an acute and chronic response to disruption 
of the RUNX1-CBFβ interaction and subsequent RUNX1 DNA-binding. Upregulated 
pathways associated with differentially expressed crisis genes include those involved in 
cell growth (e.g., MTORC1), inflammatory response and apoptosis (e.g., TNFα and p53), 
EMT, and DNA repair; in parallel, estrogen response and apical junction pathways are 
repressed. These changes are indicative of induction of apoptosis in response to 
significant cell stress and transcriptional reprogramming to support growth and transition 
from an epithelial to a mesenchymal phenotype. Comparatively, fewer pathways 
associated with the epithelial phenotype (i.e., estrogen response and cell adhesions) and 
stress responses are dysregulated in the recovery phase. Differentially expressed 
pathways during recovery (e.g., EMT, IFNɣ, and hypoxia) indicate retention of a 
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mesenchymal-like and potentially cancerous phenotype. Accordingly, proteins and 
miRNAs associated with inflammation, angiogenesis, and breast cancer development 
(i.e., MALAT1, FGF2 CXCL8, and CXCL10, among others) are upregulated in 
correlation with a transformed and likely more aggressive phenotype [206-208]. Taken 
together, this study establishes an acute and chronic response that result from loss of the 
RUNX1-CBFβ interaction and subsequent ablation of RUNX1 transcription regulation 
within the normal mammary epithelium. 
The RUNX1-CBFβ complex regulates cell cycle progression 
Little is known regarding RUNX1-mediated cell cycle control in the mammary 
epithelium. A recent study indicated that RUNX1-depleted breast cancer cells display an 
abbreviated mitosis due to an accelerated G1/S transition [129]. An additionally study in 
hair follicle stem cells, showed that RUNX1 suppresses p21 [209], a potent CDK 
inhibitor that prevents the G1/S transition and promotes apoptosis. Disruption of the 
RUNX1-CBFβ interaction, and subsequent RUNX1 DNA-binding, decreased mitotic, 
G2, and S phases populations, suggesting induction of a G1 block and apoptosis during 
the crisis phase. It is entirely possible that the observed apoptosis is because cells are 
unable to resolve the G1 block induced by inhibition of the RUNX1-CBFβ transcription 
factor complex. Taken as a whole, results from this study and those from others [129, 
209], suggest that the RUNX1-CBFβ transcription factor complex regulates the G1/S 
transition to prevent aberrant cell proliferation. Loss of RUNX1 transcriptional regulation 
accelerates the G1/S transition and increases proliferation of diseased phenotypes. 
Evidence suggests p21 plays a critical role in RUNX1-mediated cell cycle regulation 
78 
[209], however, future studies are required to determine the precise mechanism by which 
RUNX1 regulates cell cycle progression in the normal mammary epithelium. 
RUNX1 is likely a function mitotic bookmark in the normal mammary epithelium 
Immunofluorescence using a RUNX1-specific antibody revealed that RUNX1 is 
retained on mitotic chromosomes during all topologically identifiable stages of mitosis in 
normal mammary epithelial MCF10A cells. In classical immunofluorescence procedures, 
formaldehyde fixation is used to induce protein-DNA cross-linking, however, it has been 
reported that this may reduce mitotic retention of transcription factors [55, 166]. To 
prevent experimental artifacts induced by cross-linking, RUNX1 mitotic occupancy was 
observed by live-cell microscopy. Live-cell imaging confirmed RUNX1 is maintained in 
punctate foci on mitotic chromosomes throughout all stages of mitosis. ChIP-Sequencing 
revealed RUNX1 occupies genes involved in cell proliferation, growth, and phenotypic 
determination during mitosis and early G1. 
Importantly, pharmacologic inhibition of the RUNX1-CBFβ interaction decreased 
RUNX1 mitotic occupancy and dysregulated a subset of RUNX1 bookmarked genes in 
asynchronous cells. Comparison of RNA Pol II-transcribed genes differentially expressed 
during the crisis and recovery phases with genes bookmarked by RUNX1 during mitosis 
revealed significantly more overlap during the crisis phase compared with the recovery 
phase (23 and 5 genes, respectively). Because mitotic gene bookmarking by the RUNX1- 
CBFβ complex is required for immediate reactivation of the epithelial transcriptional 
program in daughter cells, it is expected that a higher percentage of bookmarked genes 
will be differentially expressed during crisis (likely reflecting an acute response) than 
during recovery. However, it must be noted that the crisis and recovery phases are not 
79 
representative of mitotically enriched populations, therefore, the regulatory relationship 
between differentially expressed genes and functionality of RUNX1 mitotic gene 
bookmarking, observed in this study, is correlative. Together, these data further support a 
phenotypic distinction between the crisis and recovery populations and suggest RUNX1 
mitotic gene bookmarking as a key epigenetic mechanism that functions to re-establish 
the mammary epithelial transcriptome as cells exit mitosis into early G1 to maintain 
cellular identity throughout successive cell divisions. 
Based on the hypothesis that RUNX1 mitotic gene bookmarking is essential for 
coordinate control of target genes directly as cells exit mitosis, it is predicted that 
RUNX1 remains tethered to its regulatory genes during mitosis and upon entry into G1. 
However, a subset of RUNX1 bookmarked genes were bound only during mitosis. 
Similarly, upon both RUNX1 depletion and disruption of the RUNX1-CBFβ interaction, 
subsets of dysregulated genes bound by RUNX1 during mitosis but not in early G1 were 
identified. These observations can be explained from a procedural standpoint as well as 
from a mechanistic standpoint, and likely reflect a combination of both. Procedurally, 
nocodazole induced mitotic synchronization was utilized for the previous ChIP- 
sequencing studies used for comparison in this study. Nocodazole is a highly potent and 
toxic chemotherapeutic. Although the nocodazole dose was selected to reduce toxic 
effects, cell viability was mildly affected. Furthermore, cell cycle synchronization was 
only approximately 70% efficient, adding another level of uncertainty to the ChIP- 
sequencing results. Therefore, the identification of differentially expressed genes that are 
bound only in mitosis may be confounded by the presence of asynchronous and 
unhealthy cells. A mechanistic explanation for RUNX1 mitotic occupancy and 
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subsequent dissociation during G1 also exists. During mitosis, RUNX1 may specifically 
mark a subset of genes involved in suppression of metabolic processes, protein synthesis, 
and cell cycle regulation. Dissociation of RUNX1 during G1 may activate these genes to 
re-establish proliferation and cellular growth. Future studies using RUNX1 inhibition or 
depletion specifically during mitosis followed by nascent transcript sequencing, for 
which conditions have been optimized, will help determine which genes, if any, are 
functionally bookmarked by RUNX1 and whether functionality is dictated by retention of 
RUNX1 during both mitosis and early G1. 
For transcriptomic analyses, it is imperative that minimal chromatin aberrations 
be imparted in order to preserve DNA structure and integrity for accurate representations 
of transcriptional landscapes, while simultaneously increasing the percentage of the 
mitotically enriched cell population. As discussed, nocodazole is a potent compound 
which can both disrupt chromatin integrity and decrease cell viability and the selected 
dose does not efficiently synchronize all cell in mitosis. Furthermore, nocodazole is a 
microtubule polymerization inhibitor, that blocks cells in metaphase, thus potentially 
excluding regulatory events that may be specific to prophase and prometaphase. To 
obtain a mitotically pure population, cells must be physically shaken-off. However, cells 
obtained from mitotic shake-off did not readily progress through the cell cycle. Based on 
these observations, a CDK1 inhibitor, RO-3306, was used for mitotic synchronization. 
This drug alleviates induction of chromosomal aberrations as well as the need for a 
mitotic shake-off and enriches cells at the G2/M boundary with >80% efficiency to allow 
synchronized progression of a more purified cell population through mitosis and into 
early G1. 
81 
This study has confirmed the ability of non-radioactive precision nuclear run on 
(PRO) to isolate nascent transcripts in MCF10A cells. Inhibition of transcription by 
Actinomycin D revealed significantly decreased expression of nascent transcripts, 
validating isolation methods by biotin run-on and streptavidin bead capture. Together, 
conditions for mitotic synchronization and release and methods for isolation of nascent 
transcripts for analysis by RNA-sequencing or qPCR have been confirmed. 
Finally, this study proposes specific pharmacologic inhibition of the RUNX1- 
CBFβ interaction at mitosis to study the functional role of RUNX1 as an essential mitotic 
bookmark to maintain the normal mammary epithelial phenotype throughout successive 
cell divisions. In order to optimize specific disruption of RUNX1 DNA-binding at 
mitosis, the kinetics and treatment time required for disruption of RUNX1 DNA-binding 
should be determined for the active CBFβ inhibitor, AI-14-91, in MCF10A cells. Based 
on studies by Illendula and colleagues, performed in SEM leukemia cells [139], six hours 
of CBFβ inhibition prior to completion of mitotic synchronization is suggested as a 
starting point. 
Because use of a pharmacologic inhibitor adds potential effects non-specific to 
mitosis (e.g. disruption of cytoplasmic CBFβ functions and effects induced prior to 
mitosis), to transcriptomic analyses, a stable cell line expressing genetically modified 
RUNX1, tagged for inducible degradation, should be developed. Such a cell line will 
allow for specific and immediate depletion of RUNX1 at mitosis. Of course, addition of 
molecular structures to proteins may alter tertiary and quaternary protein structures which 
may alter protein function and localization. These possible effects must be carefully 
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considered in the design of a specific RUNX1 degron and upon analyzing data obtained 
from this system. 
Concluding remarks 
In summary, the results reported in this dissertation establish that the interaction 
between RUNX1 and its binding partner CBFβ is required for maintenance of the normal 
mammary epithelial phenotype. Pharmacological disruption of the RUNX1-CBFβ 
interaction dysregulates pathways involved in inflammation, proliferation, cell growth, 
and epithelial cell identity, eliciting an epithelial-to-mesenchymal transition. Evidence 
suggesting the potential role of RUNX1 mitotic gene bookmarking as an essential 
epigenetic mechanism to maintain the normal mammary epithelial phenotype is 
presented, and methods for interrogating its functionality are described. Future studies 
performed in ER+ cell lines are necessary as RUNX1 is most commonly mutated in ER+ 
breast tumors, suggesting loss of RUNX1 mitotic gene bookmarking may drive 
development of this tumor subtype. Finally, studies in aggressive, triple-negative breast 
cancer cells lines (e.g. MDA-MB-231) may reveal an alternate subset of RUNX1 target 
genes during mitosis and provide insight into the correlation between increased RUNX1 
expression in triple-negative breast cancers and poor prognosis. Together, these studies 
will identify novel targets for therapeutic intervention across a variety of breast cancer 
subtypes. 
Funding
 This project was made possible by funding from the National Cancer Institute and 







This study primarily utilized the normal human mammary epithelial MCF10A cell 
line. Parental MCF10A cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM)/F-12 50/50 mixture base medium supplemented with 5% horse serum, 10 
ug/mL human insulin, 20 ng/mL human epidermal growth factor, 100 ng/mL cholera 




Parental MCF10A cells were synchronized in late G2/M by two independent 
methods to optimize synchronization efficiency and reduce cytotoxic effects and 
decreased cell viability. 
Mitotic Synchronization by CDK1 inhibition (RO-3306): 
 
To synchronize cells at the G2/mitosis transition, MCF10A cells were cultured in 
complete growth medium additionally supplemented with 9 µM RO-3306 CDK1 
inhibitor. Control cell populations were treated with equivalent volumes of dimethyl 
sulfoxide (DMSO) as inhibitor treated populations. Mitotic and asynchronous cell 
populations were harvested 20 hours post respective treatments. To obtain an early G1 
population, G2 arrested cells were washed three times with warm 1X phosphate-buffered 
saline (PBS), cultured in RO-3306-free medium for three hours at 37ºC, then harvested 
for downstream analyses and applications. 
Mitotic Synchronization by Nocodazole: 
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MCF10A cells were treated with 50 ng/mL nocodazole diluted in DMSO for 16 
hours to synchronize cells in early mitosis. Control cell populations were treated with 
equal volumes of DMSO. To obtain a mitotically pure population, blocked cells with 
harvested by mitotic shake-off in 0.05% trypsin-EDTA diluted in 1X PBS for three 
minutes. Five mL of fresh culture medium were added three minutes after shake-off to 
deactivate trypsin and plates were washed with the medium four times to collect shaken- 
off cells. Cells were collected by centrifugation at 1500 rpm for five minutes and washed 
once in 1X PBS to remove remnant medium. To obtain an early G1 population, blocked 
cells were washed three times with warm 1X PBS, incubated in fresh, nocodazole-free 
growth medium for three hours at 37ºC, then harvested for downstream analyses and 
applications. 
Disruption of RUNX1 DNA-binding 
The small molecule inhibitor of CBFβ, AI-14-91, and its structurally similar 
inactive counterpart AI-4-88 and JP-1-32, were generously provided to us by John H. 
Bushweller (University of Virginia). Inhibitors were dissolved in DMSO. MCF10A cells 
were cultured in 20 µM CBFβ inhibitor or control compound treated growth medium to 
examine the effects of RUNX1 DNA binding disruption. 
To analyze the effects of long-term disruption of RUNX1-DNA binding, 
MCF10A cells were cultured in AI-14-91 supplemented growth medium for 24 and 48 
hours. These timepoints were combined into a “crisis” category. In parallel, two 
MCF10A cell populations were cultured in AI-14-91 supplemented growth medium for 
five days. At day five, inhibitor-treated growth medium was removed, remaining cells 
were washed with 1X PBS and allowed to recover in inhibitor-free growth medium for 
85 
 
four and seven days. These two populations were categorized into one “recovery” 
population. 
RNA Isolation, cDNA synthesis, qPCR, and RNA-seq library preparation 
 
Total RNA was isolated from MCF10A cells by TRIzolTM Reagent and Direct- 
ZolTM RNA MiniPrep Isolation Kit. cDNA was synthesized with the SuperScript IV® 
First-Strand Synthesis System for RT-PCR following the manufacturer’s protocol. cDNA 
was quantified using Qubit 2.0 Fluorometer and equal quantities of cDNA template (500 
pg/µL) were analyzed by qPCR. Homo Sapiens specific qPCR primers (Appendix VIII) 
were designed using Primer-Blast and reference sequences provided by the National 
Center for Biotechnology Information. Forward and reverse primers spanned at least one 
exon junction with lengths were no larger than 25 base pairs with a total product length 
no greater than 200 base pairs. Primer efficiencies were determined to validate 
functionality. Only primers with an efficiency greater than 85 were used for further 
analysis. β-actin and GAPDH were used as internal controls. Results were analyzed by 
double delta Ct analysis to determine the relative expression of target genes to internal 
controls. 
RNA-sequencing, differential expression analysis, and pathway analysis 
 
The following section is modified from Rose, J. T.,/Moskovitz, E., et al. (2020), 
“Inhibition of the RUNX1-CBFβ transcription factor complex compromises mammary 
epithelial cell identity: a phenotype potentially stabilized by mitotic gene bookmarking”, 
Oncotarget. 
RNA-seq libraries were prepared in triplicate. RNA was isolated using Direct-zol 
RNA MiniPrep and was quantified and assayed for RNA integrity by Bioanalyzer. 
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Following the removal of ribosomal RNA, the RNA pool was reverse transcribed, 
amplified, purified, and ligated following the manufacturer’s protocol for SMARTer 
Stranded Total RNA Sample Prep Kit. cDNA libraries were assayed for quality control 
by Bioanalyzer. After cDNA quality validation, generated libraries were sequenced by 
the University of Vermont Cancer Center – Vermont Integrated Genomics Resource 
(VIGR). Twenty-four hour and 48-hour counts were grouped together into one “crisis” 
category and the day 4 recovery and day 7 recovery counts were grouped together into 
one “recovery” category. Treatment groups were compared with untreated MCF10A 
cells. After demultiplexing and quality filtering, reads were aligned to hg38 using 
Gencode (GRCh38.p13). As a reference, annotation with STAR (v2.5.2a) [210] aligned 
reads were then counted using HT-Seq [211]. Differential gene expression was analyzed 
using DESeq2 in R v.3.5.1 [212]. Parameters for significant differential expression were 
base mean expression greater than five, absolute log2 fold change greater than one, and a 
p-value less than 0.05. Pathway analysis was performed using Gene Set Enrichment 
Analysis v6.3. 
Precision nuclear run-on (PRO) 
 
For analysis of nascent transcripts, precision nuclear run-on was used. Nascent 
transcripts were biotinylated, pulled-down, and enriched following the protocol by 
Mahat, D. B., et al [213]. This procedure allows for base-pair-resolution and genome- 
wide mapping of nascent transcripts based on RNA polymerase activity. 
For validation of procedural functionality in MCF10A cells, 1-Biotin run-on was used, 
and pull-downs were enriched only once (through step 48). To validate nascent pull- 
downs, MCF10A cells were treated with 1 µg/mL actinomycin-D, dissolved in DMSO, 
87 
 
for 6 hours. Control cells were treated with equivalent volumes of DMSO. After 6 hours 
of treatment, cells were immediately harvested exactly as instructed by the protocol. Post 
biotin pull-down and RNA enrichment, cDNA was synthesized by volume. Expression of 
target genes were analyzed by RT-qPCR. Results were analyzed by double delta Ct 
analysis to determine the relative expression of target genes to internal controls. 
Protein isolation, quantification, and SDS-Page/Western blot 
 
For total protein isolation cells were harvested and suspended in 250 µL RIPA 
buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 1mM SDS, 0.1 M EDTA, 1X 
protease inhibitors, and 1X MG132), incubated on ice for a minimum of 30 minutes then 
subjected to sonication on a QSonica Sonicator at an amplitude of 30 for 70 seconds total 
in 10 second intervals interspaced by 30 second break periods. Post sonication, cell 
lysates were spun at 15,000 rpm for 15 minutes at 4ºC. Total protein concentration of the 
supernatant was determined by a bicinchoninic acid (BCA) assay using a bovine serum 
albumin (BSA) standard curve. 
For Western Blot 30 ug of protein was separated on a were separated in a 10% 
acrylamide gel (30% w/v and 37.5:1 acrylamide:bis-acrylamide) with a 4% acrylamide 
stacking gel. Samples were run at 160 V until the samples began to enter the separating 
gel (~13-15 minutes), then the voltage was increased to 200 V until the die front reached 
the edge of the gel. Protein was transferred onto a polyvinylidene fluoride (PVDF) 
membrane by semi-dry transfer on an owl HEP-1 apparatus. Post protein transfer, 
membranes were blocked in 5% non-fat dry milk in PBS-T. To assess proteins of interest, 
all primary antibodies (Appendix II) (except beta-actin which was diluted 1:3000) were 
diluted 1:1000 in 1% non-fat dry milk in PBS + 0.1% Tween 20 (PBS-T). Membranes 
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were incubated with primary antibody at 4ºC overnight or at room temperature for three 
hours. Post primary antibody incubation, membranes were washed four times in PBS-T at 
room temperature then incubated in secondary antibody diluted 1:3000 in 1% non-fat dry 
milk in PBS-T for one hour at room temperature. Membranes were washed four times 
with PBS-T at room temperature then developed in 1:1 ClarityTM Western ECL Blotting 
Substrates and imaged using Molecular Imager® Chemi DocTM XRS+ Imaging System. 
Fluorescence-activated cell sorting (FACS) 
 
H3pS28 and DNA Staining 
 
A minimum of one million MCF10A cells were harvested, centrifuged at 1500 
rpm for 5 minutes, washed once with 1X PBS, and spun down a second time as 
previously described. Cells were either flash frozen in liquid nitrogen for storage at -80ºC 
or immediately fixed in 1 mL ice-cold 75% ethanol, added dropwise while the cells were 
gently vortexed, and incubated at 4ºC for 30 minutes. The remaining spins were all 
performed at 2000 rpm for 5 minutes. Cells were spun down and the ethanol supernatant 
was removed. Cells were washed twice (500 µL per wash) in FACS buffer (5% FBS in 
PBS) with intermittent spins and supernatant removal. Cells were then permeabilized in 
100 µL permeabilization buffer (0.25% Triton X-100 in PBS) for 15 minutes at room 
temperature, washed once in 1 mL permeabilization buffer, spun down, and the 
supernatant was removed. Cells were incubated in AF647-conjugated antibody against 
H3pS28 diluted 1:50 in permeabilization buffer for 30 minutes at room temperature in the 
dark. Cells were washed twice with FACS buffer with intermittent spins and removal of 
supernatant. Finally, cells were resuspended in 500 µL PI/RNase stain and incubated at 
room temperature for 15 minutes in the dark. Cells were either stored at 4ºC or analyzed 
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immediately by flow cytometry at the Harry Wood Bassett Flow Cytometry and Cell 
Sorting Facility, University of Vermont College of Medicine. 
H3pS10 and DNA Staining 
A minimum of one million MCF10A cells were harvested by centrifugation as 
indicated in the previous subsection. Cells were either flash frozen in liquid nitrogen for 
storage at -80ºC or immediately fixed in 1 mL ice-cold 75% ethanol, added dropwise 
while the cells were gently vortexed, and incubated at 4ºC for 30 minutes. The remaining 
spins were all performed at 2000 rpm for 5 minutes. Cells were spun down and the 
ethanol supernatant was removed. Cells were washed twice in excess PBS to remove 
ethanol and incubated in 100 µL primary H3S10ph antibody diluted 1:50 in FACS buffer 
(5% FBS in PBS) for one hour at room temperature. Cells were washed twice by 
centrifugation in incubation buffer then resuspended in 100 µL fluorochrome-conjugated 
secondary antibody diluted 1:1000 in incubation buffer for 30 minutes at room 
temperature. Finally, cells were washed twice by centrifugation in FACS buffer and 
resuspended in 500µL PI/RNase stain and incubated for 15 minutes at room temperature. 
Cells were either stored at 4ºC or analyzed immediately by flow cytometry at the Harry 
Wood Bassett Flow Cytometry and Cell Sorting Facility, University of Vermont College 
of Medicine. 
Cell imaging 
Live cell microscopy 
A previously reported [214] mammalian expression plasmid, expressing the 
RUNX1 protein, fused in frame with enhanced green fluorescent protein (EGFP) was 
used for this study. 
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To visualize RUNX1 localization with mitotic chromatin in live cells, MCF10A 
cells were plated onto 0.5% gelatin w/v coated glass coverslips. Cells were cultured for 
24 hours then transfected at 40-60% confluency with 0.5 ug RUNX1-EGFP DNA 
introduced by either nucleofection or Lipofectamine TM 3000 transfection reagent 
following the reagent ratios provided by the manufacturers. Coverslips were harvested at 
16 and 24 ours timepoints post transfection. Directly prior to harvest, cells were washed 
briefly once with 1X PBS and stained with 1 ug/mL Hoechst 33258 DNA stain for 15 
minutes at room temperature. Coverslips were immediately mounted onto glass slides for 
microscopy analysis. 
Fluorescent Light and Confocal Microscopy 
 
The following section is modified from Rose, J. T./Moskovitz, E., et al. (2020), 
“Inhibition of the RUNX1-CBFβ transcription factor complex compromises mammary 
epithelial cell identity: a phenotype potentially stabilized by mitotic gene bookmarking”, 
Oncotarget. 
Images of live cells were initially captured using a Zeiss Axio Imager.Z2 
fluorescent microscope and Hamamatsu ORCA-R2 C10600 digital camera. Images were 
processed using ZEN 2012 software. To ensure specific co-localization with mitotic 
chromatin, samples were imaged with a Nikon A1R-ER laser scanning confocal 
microscope (Nikon, Melville, NY, USA). The Hoechst signal was excited with a 405 nm 
laser and the EGFP was excited with a 488 nm laser. Z-stack images were acquired with 
the galvano scanner at a frame size of 1024 X 1024 pixels with an Apo TIRF 60X 
objective lens (N.A. 1.49) zoom of 2 and 1.2 Airy Unit pinhole setting. Z-stacks of at 




Three biological replicates of each Western Blot were performed. Protein bands 
were quantified using equal area measurements between experimental conditions in 
Molecular Imager®. Band intensities for each protein of interest were normalized to the 
internal control protein beta-actin. Normalized protein band intensities were averaged 
between the three biological replicates. 
FACS 
Population were gated for single cells. The cell cycle analysis tool in FloJo was 
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Supplemental Figure 1. Long-term disruption of the RUNX1-CBFβ interaction alters expression 
of RUNX proteins and EMT markers. Three biological replicates of Western blots for RUNX1, 
RUNX2, epithelial marker E-cadherin, and mesenchymal marker (top panels to panels second from the 
bottom, respectively) in MCF10A whole cell lysates. Blot performed on individual membranes are 
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Supplemental Figure 2. Prolonged disruption of the RUNX1-CBFβ interaction in MCF10A cells 
decreases phosphorylation of late G2 and mitotic histone markers. FACS analysis of asynchronous 
MCF10A populations. Populations are ungated. Top panels: MCF10A cells treated with 20 µM inactive 
compound (AI-4-88) for 24 hours, 48 hours, and 72 hours, from left to right, respectively. Bottom panels: 
MCF10A cells treated with 20 µM active compound (AI-14-91) for 24 hours, 48 hours, and 72 hours, 
respectively. A) Populations labeled with a fluorophore conjugated H3pS28 specific antibody and PI 
stain. B) Populations labeled with a primary H3pS10 specific antibody visualized with a fluorophore 
conjugated Alexa secondary antibody and PI stain. Event numbers vary between inactive and active 
compounds, likely due to progressive cell death observed with the active compound. Accordingly, the 
mitotic percentage for populations treated with the active compound, may be overrepresented. 
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Supplemental Figure 3. Long-term disruption of the RUNX1-CBFβ interaction alters expression 
of proteins involved in cell cycle control. Three biological replicates of Western blots for cell cycle 
regulators cyclin B1, CDK2, and total p53 (top panels to panels second from the bottom, respectively). 
Blots performed on individual membranes within biological replicates are depicted with their 
corresponding β-actin control blots (bottom panels). Whole cell lysates were harvested from MCF10A 
cells (P10A), MCF10A 24-hour and 48-hour crisis timepoints (24 hr and 48 hr, respectively), and Day 4 
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Appendix I: Abbreviations 
AML = acute myelogenous leukemia 
AR = Androgen receptor 
BCA = Bicinchoninic acid 
BET = bromodomain and extra-terminal domain 
BSA = Bovine serum albumin 
CBFβ = Core binding factor β 
CBP = CREB binding protein 
CML = Chronic myelogenous leukemia 
CNS = Central nervous system 
DE = Differential expression 
DMEM = Dulbecco’s Modified Eagle Medium 
DMSO = Dimethyl sulfoxide 
ECM = Extracellular matrix 
EGF = Epidermal growth factor 
EGFP = Enhanced green fluorescent protein 
EMT = Epithelial-to-mesenchymal transition 
ER = Estrogen receptor 
FACS = Fluorescence activated cell sorting 
FBS = Fetal bovine serum 
FGF = Fibroblast growth factor 
G1 = Gap 1 
G2 = Gap 2 
GSEA = Gene set enrichment analysis 
HER2 = Human epidermal growth factor receptor 2 
HSC = Hematopoietic stem cell 
FIJI = Fiji is just ImageJ 
M = Mitosis 
MET = Mesenchymal-to-epithelial transition 
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NMTS = Nuclear matrix targeting signal 
PBS = Phosphate buffered saline 
PDGF = Platelet derived growth factor 
PR = Progesterone receptor 
PRO = Precision nuclear run-on 
PTHLH = Parathyroid hormone-like hormone 
PVDF = Polyvinylidene fluoride 
RHD = Runt homology domain 
RTK = Receptor tyrosine kinase 
RUNX = Runt-related transcription factor 
S = Synthesis 
TBP = TATA binding protein 
TLE = transducin-like enhancer of split 
TNBC = Triple-negative breast cancer 
TSS = Transcriptional start site 
UBF1 = Upstream binding factor 1 
VIGR = Vermont Integrated Genomics Resource 












4336S Rabbit 1:1000 




12556S Rabbit 1:1000 




14472S Mouse 1:1000 




6260 Mouse 1:1000 




752 Rabbit 1:1000 















Appendix III: Cloning 
Reagent Company Location 
EGFP cDNA Clontech Palo Alto, CA 
pcDNA3 Invitrogen Carlsbad, CA 
Appendix IV: Precision nuclear run-on (PRO) 
Biotin nuclear run-on 
Reagent Company Location 
Biotin-11-ATP Axxora San Diego, CA 
Biotin-11-CTP Axxora San Diego, CA 
Biotin-11-GTP Axxora San Diego, CA 
Biotin-11-UTP Axxora San Diego, CA 
ATP, 100mM Bio Basic Inc. Ontario, Canada 
GTP, 100mM Bio Basic Inc. Ontario, Canada 
UTP, 10m0M Bio Basic Inc. Ontario, Canada 
P-30 column,
RNase-free 
Bio-Rad Hercules, CA 
Streptavidin 
M280 beads 
Invitrogen Carlsbad, CA 
Other Chemical and Reagents 
Reagent Company Location 
Tri Reagent®, LS Sigma-Aldrich St. Louis, MO 
Chloroform Thermo Fischer 
Scientific 
Waltham, MA 










9282S Rabbit 1:1000 
BD Biosciences San 
Hose, 
CA 





3465S Rabbit 1:50 
Invitrogen Carlsbad, 
CA 
21206 D α R 1:1000 
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Appendix V: RNA isolation, cDNA synthesis and RNA-Seq library builds 
Reagent Company Location 

















Takara Bio Mountain 
View, 
CA 
Appendix VI: Western blot 
Reagent Company Location 
Bovine Serum 
Albumin 











Bio-rad Technologies Hercules, 
CA 
Appendix VII: General reagents 
Cell culture 
Reagent Company Location 
DMEM/F-12 
50/50 
Corning TM Corning, NY 
Horse serum GIBCO® Grand Island, NY 
Fetal Bovine 
Serum (FBS) 
Peak Serum Wellington, CO 
Penecillin- 
Streptomycin 
GIBCO® Grand Island, NY 





PeproTech Rocky Hill, NJ 
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Cholera toxin Thermo Scientific Swedesboro, NJ 
Hydrocortisone Sigma-Aldrich St. Louis, MO 
Human insulin Sigma-Aldrich St. Louis, MO 
AI-14-91 University of Virginia (Bushweller Lab) Charlottesville, VA 
AI-4-88 University of Virginia (Bushweller Lab) Charlottesville, VA 
RO-3306 Sigma-Aldrich St. Louis, MO 
Nocodazole 









Invitrogen Carlsbad, CA 
DNA Stains 
Reagent Company Location 
PI/RNase Stain BS Biosciences Franklin Lakes, NJ 
DAPI Sigma-Aldrich St. Louis, MO 
Hoechst 33258 Molecular Probes TM Eugene, OR 
Appendix VIII: qPCR primers 
Gene Name Forward Sequence Reverse Sequence 
Beta-actin AGCACAGAGCCTCGCCTT CGGCGATATCATCATCCA 
CDH1 GGGGTCTGTCATGGAAGGTG CGACGTTAGCCTCGTTCTCA 
GAPDH AGGGCTGCTTTTAACTCTGGT CCCCACTTGATTTTGGAGGGA 
HPRT TGCTGACCTGCTGGATTACA TCCCCTGTTGACTGGTCATT 
hpre-rRNA CCGCGCTCTACCTTACCTAC GAGCGACCAAAGGAACCATA 
H28S CCGATGTCTTCGAGGTTCTC ATCTGAACCCGACTCCCTTT 
RUNX1 GTCGAAGTGGAAGAGGGAAA CCGATGTCTTCGAGGTTCTC 
Appendix IX: Instruments 
Reagent Company Location 















Molecular Imager® Chemi DocTM XRS+ Imaging System Bio-Rad 
Laboratories 
Hercules, CA 
Owl HEP-1 semi-dry transfer apparatus Invitrogen Carlsbad, CA 
Nikon A1R-ER laser scanning confocal microscope Nikon Melville, NY 
Zeiss Axio Imager.Z2 fluorescent microscope Carl Zeiss AG Oberkochen, 
Germany 





Appendix X: Analytical Programs: 
 
Program Company Location 
Gene Set Enrichment Analysis v6.3 Broad Institute, 
Inc., MIT, UC 
San Diego 
Boston, MA 











Image LabTM Software Bio-Rad 
Laboratories 
Hercules, CA 
 
